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The Importance of Allies
Regarding the article on Drs. 
Ment and Duncan: in ser-
vice of focusing the issue on 
women, you downplayed the 
role of Dr. Duncan, senior—Dr. 
Ment’s husband, and a pre-
eminent physician. As part of 
a two-academic-career Yale 
household (my husband is a Yale 
PhD), I suspect this inadver-
tently takes Dr. Ment’s career 
out of its essential context. For 
them both to succeed, surely a 
tremendous amount of behind-
the-scenes sharing of roles and 
renegotiating of responsibilities 
had to occur. 
Yale has a remarkable number 
of couples in medicine who have 
excelled at this (so many that 
when I was a medical resident 
we had a whole trivia category 
on married Yale physician cou-
ples with different last names). 
They served as role models for 
younger physicians who aspired 
to balance career, marriage, and 
children with their equally tal-
ented and dedicated partners.
Dena Rifkin, MD ’01 
LaJolla, Calif.
Remembering  
Sofia Simmonds, PhD 
(and others)
I was very surprised that 
there was no mention of Sofia 
Simmonds in your recent issue 
of Yale Medicine Magazine: 
A Century of Women at Yale 
School of Medicine. I was a grad-
uate student from 1952 to 1957 
in the Microbiology Department 
across Cedar Street from the 
Biochemistry Department. The 
Biochemistry Department 
was unusual for the number of 
women graduate students there, 
among them Maxine Singer, PhD. 
Sofia Simmonds, PhD, was the 
wife of Joseph Fruton, PhD, the 
biochemistry department’s chair. 
In retrospect, the large number 
of female graduate students was 
probably due to the influence of 
Professor Simmonds.
Maurice Margulies, PhD ’57 
Rockville, Md.
I am surprised that your issue 
on a century of women at Yale 
Medical School did not men-
tion Professor Sofia Simmonds 
of what was then Yale’s 
Biochemistry Department, and 
which is now a component of 
the Department of Molecular 
Biophysics and Biochemistry 
(MB&B). Not only did she co-
author (with Joseph Fruton, her 
husband) the first comprehen-
sive biochemistry textbook, 
which they updated in a second 
edition, but she also received 
the Garvan Medal from the 
American Chemical Society for 
contributions to chemistry by 
a female scientist. Even more 
importantly, she served as a role 
model and source of inspiration 
for female students desiring to 
enter the field of biochemistry.
Gerald J. Putterman, PhD ’65 
Hamden, Conn.
Editor’s note: 52 pages might 
seem like a lot, but even that 
wasn’t sufficient to highlight all 
the remarkable accomplish- 
ments of women graduating 
from Yale School of Medicine 
or on the faculty. Simmonds is 
represented on the “100 Years 
of Women in Medicine Website,” 
and can be found here: medicine.
yale.edu/centuryofwomen.
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  The bottom-up revolution driving  
microbiome research at Yale
f u el ed by technologic a l br e a kthroughs  and a wealth 
of information gleaned from private research and government-funded 
programs, lines of inquiry into human and non-human microbiomes 
have proliferated in recent years. Robert J. Alpern, MD, dean and Ensign 
Professor of Medicine, describes the field’s blossoming significance, and 
how YSM has fostered research in New Haven.
How have attitudes toward the microbiome evolved during your professional career? While 
in the past, there were interesting observations about the potential importance of the 
microbiome, today, the microbiome is one of the more exciting frontiers of medicine. 
While it hasn’t fully defined itself in terms of its importance to homeostasis, or how 
useful it will be in preventing and treating disease, there’s accumulating evidence that 
it will be very important to both. “Health” as we think of it may actually be the result 
of an interplay between our individual genome and the composition of our microbiome 
and the effects of both on our homeostatic processes, so it’s a vital area of research. 
What has the School of Medicine done to prepare for increased activity with the microbiome?  
First, we’ve recruited outstanding scientists. Second, we’ve built facilities to support 
those scientists. We’ve staked out a leadership position in this field and ensured that we 
have a framework to capitalize on what appears to be a likely upcoming boom of inves-
tigators (and investigations) into the microbiome. From the standpoint of the school, we 
want to establish core facilities that allow any researcher, no matter their area of inter-
est, the ability to work with the microbiome.
Was that by design? Yes and no. A number of departments decided to recruit in this area. 
We agreed to build facilities to support their efforts. I think this is a typical bottom-up 
success story where departments decided the scientific priorities, the areas they think 
Yale needed to investigate, and YSM supported those priorities. Then, once the right 
people were here, and the facilities came online, other people who weren’t necessarily 
working in the area chose to expand their research.
How has this affected the field of nephrology? The kidney is significantly affected by 
immunologic diseases, a class of disease that has seen significant correlative over-
lap with microbiome research. One disease that affects the kidney, IgA nephropathy, 
involves an antibody that occurs in mucosal interfaces. I wouldn’t be surprised if it 
turns out that IgA nephropathy was influenced by the microbiome. It’s exciting to 
be a doctor or researcher at Yale today, with all these longstanding mysteries being 




   Yale and the VA:  
  Joined at the hip
on the first day of her residency rotation at the va 
hospital in West Haven, Susan Kashaf, MD, MPH, treated 
Kevin Barbour, a Vietnam War veteran. Barbour was 
exasperated by lingering pain from earlier knee surgery—
and he let her know about it. 
Caption
 
It was a rough start for a young 
doctor. “He scared the heck out 
of me,” recalls Kashaf.
Today, 20 years later, Kashaf 
is an attending physician at the 
VA and an associate professor 
of medicine at Yale School of 
Medicine—and Barbour is still 
one of her patients. She has a 
thank-you card that he sent her 
after she helped him quit smok-
ing. “It’s a nice reminder of what 
we do,” says Kashaf.
Barbour says he rarely sends 
thank-you notes, but, he felt 
compelled to reach out to Kashaf. 
“She has been my primary care 
doctor for 20 years. It’s nice to 
know that somebody is watch-
ing over me,” he says.
The warm feelings shared 
by Kashaf and Barbour are 
emblematic of the deep and 
multifaceted relationship 
between Yale School of Medicine 
and the VA Connecticut 
Healthcare System in West 
Haven that goes back more than 
60 years. People involved say the 
tie is critically important to the 
delivery of high-quality medical 
care to veterans in Connecticut—
and to vets with complex cases 
from across New England. 
The majority of physicians 
who work at the VA in West 
Many doctors at Yale, 
including Susan Kashaf, 
right, and hospital 
resident Mary Barden, 
treat veterans at the VA 
Connecticut Healthcare 
System’s West Haven 
facility. Kashaf has been 
providing service at the 
VA since her residency 
20 years ago, and has de-
veloped lasting relation-
ships with her patients.
ymm.yale.edu4
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a unique national system that 
offers a seamless web of services 
from primary care to specialized 
services to hospital to geriatric 
and nursing care. When done 
correctly, it’s a national model for 
providing health care,” says John 
Booss, MD, professor emeritus at 
Yale School of Medicine, formerly 
the national program director for 
the VA’s neurology service.
When Theodis Fenn Sr. 
returned from Vietnam as a 
combat infantryman in 1967, he 
suffered from malaria, hepatitis, 
anxiety, and burns on his feet 
from a base camp accident—and 
had been exposed to Agent 
Orange, the toxic defoliant. His 
initial encounters with the VA 
were disappointing. “They never 
addressed my problems,” he says.
But eventually Fenn obtained 
Daniel Federman, MD, a profes-
sor of medicine at Yale, as his 
primary care physician, and 
things turned around. Fenn has 
received treatment for PTSD, lung 
and prostate cancer, diabetes, 
high blood pressure, and chronic 
abdominal pain. “Dr. Federman is 
my lifesaver. Without him, I’d be 
dead,” says Fenn.
Leaders at Yale and the VA say 
veterans like Fenn who have com-
plex health problems benefit from 
the expertise in diagnosis and 
treatment that medical school 
faculty can offer. For instance, 
Yale and the VA Connecticut 
Healthcare System helped define 
and establish PTSD as a diagnosis 
back in 1980, and today research-
ers at the VA are developing inno-
vative treatments for it. 
In return for their dedication 
to better health care for veter-
ans, Yale faculty physicians and 
students who practice at the VA 
get tremendous satisfaction from 
treating veterans, who are typi-
cally grateful and willing to vol-
unteer for studies that might help 
their comrades. A number of Yale 
faculty members treat patients at 
the VA without compensation.
Some veterans become like 
family to the med students and 
residents. Uyen To, MD, assis-
tant professor of medicine and 
a Yale transplant hepatology 
fellow who did her residency 
at Yale as well, says she became 
particularly close to one elderly 
man—even telling him about her 
wedding plans. At one point he 
was near death. He grabbed her 
hand and vowed, “I’m not going 
to die before you get married.” 
He pulled through.
For Yale’s medical students, 
residents and fellows, the West 
Haven hospital provides an excel-
lent place to learn and practice 
in a hands-on environment. In a 
typical year, more than 200 medi-
cal students complete clinical 
rotations there in a wide range 
of medical specialties, working 
closely with attending physicians 
who also provide classroom train-
ing. At any given time, 15 percent 
of the more than 1,100 residents 
and fellows are on rotations at the 
VA—during which time the VA 
covers their salaries.
“The patients want to help 
them learn. They have incred-
ibly interesting medical histo-
ries and social histories around 
Haven have faculty appoint-
ments at Yale. “Our patients 
get the latest advances in care 
applied to their problems. They 
get the depth and expertise of 
a medical staff associated with 
Yale, and they can get consul-
tations with the top experts 
at Yale and Yale New Haven 
Hospital,” says Michael Ebert, 
MD, the chief of staff at VA 
Connecticut. At Yale, he is a pro-
fessor of psychiatry and associ-
ate dean for veterans’ affairs.
Yale School of Medicine lead-
ers say the association provides 
Yale medical students, residents, 
and fellows with valuable hands-
on training. Plus, the VA’s a  
fertile environment for conduct-
ing medical research. “Yale’s 
longstanding relationship with 
the VA is a win-win. It’s been 
mutually beneficial for the medi-
cal students, residents, and fel-
lows who train there; the faculty 
who conduct research there; 
and the veterans who receive 
exceptional care,” says Robert J. 
Alpern, MD, dean of Yale School 
of Medicine and Ensign Professor 
of Medicine (Nephrology).
These days, the Veterans 
Health Administration is under 
attack from critics who want to 
replace it with private health 
care. However, leaders at VA 
Connecticut and Yale say the VA 
system provides outstanding 
lifelong care in most cases to a 
patient population whose medi-
cal issues tend to be complex 
and whose physical ailments 
are often compounded by men-


















A safer way to live with 
guns: residents and 
doctors at Yale learned 
first-responder tech-
niques this fall, in order 
to spread knowledge 
to parents and children 
who might be exposed 
to shootings. If legisla-
tion limiting access 
to firearms is not 
forthcoming, everyone 
needs to know first aid.
For more on the classes, 
visit ymm.yale.edu/safe
care available, and to improving 
care for generations to come via 
research and teaching. Every 
faculty member interviewed for 
this story said they chose the 
VA because it’s so gratifying to 
help veterans.
Veterans interviewed returned 
the warm feelings. Vietnam 
vet Bill Broumas shunned the 
VA after he returned from the 
war. He received private insur-
ance through his employer. But a 
few years ago he decided to give 
the VA another chance—partly 
because of the Yale connection. 
Now he’s a fan. “Every single per-
son I meet there—they’re totally 
interested in me,” he says. “They 
all treat me like a human being.”
—Steve Hamm
»
Ten years of music  
from Yale Medical 
Symphony Orchestra
The Yale Medical Symphony 
Orchestra (YMSO) kicked off 
its 10th year with a concert in 
Harkness Auditorium that was 
filled to the rafters. “We love 
looking out and seeing a packed 
auditorium,” said symphony 
conductor Robert Smith to the 
crowd, which used every seat 
and included people lining the 
walls of the auditorium. “Eight 
years ago, we had only about a 
third of the auditorium filled.”
Now a group of more than 
50 musicians from the School 
of Medicine and Yale commu-
nity perform composers like 
Tchaikovsky and Brahms to a 
their military time, so it’s a 
rich learning experience,” says 
Seonaid Hay, MD, assistant pro-
fessor of medicine and associate 
program director of the Yale 
Traditional Internal Medicine 
Residency Program at the VA.
Yale faculty members teach-
ing at the West Haven VA have 
introduced a number of innova-
tions there. One is the Center 
of Excellence in Primary Care 
Education, in which faculty 
members teach residents how to 
provide primary care through 
interprofessional teams. At the 
VA Connecticut clinics, residents 
work with teams that include 
nurses, medical assistants, 
psychologists, pharmacists, 
and others to provide care for 
patients tailored to individual 
needs. The program started in 
a few clinics and now includes 
most of the clinics at the West 
Haven facility.
The VA provides tremendous 
research opportunities for stu-
dents, junior faculty members, 
and senior faculty alike. The 
VA is a fertile environment for 
research partly because of its 
size and scope. Researchers can 
study large groups of patients at 
VA medical centers around the 
country. Because the VA was a 
pioneer in electronic medical 
records in the 1970s, much of its 
historic data is easily accessible.
“Another attraction is the 
patients. They’re willing to 
participate in research because 
they want to help their buddies. 
There’s an altruistic drive,” says 
Fred Wright, MD, the director 
of research at VA Connecticut 
and a professor of medicine 
(nephrology) and of cellular and 
molecular physiology at Yale. 
The VA Connecticut Healthcare 
System has 25 labs in West Haven, 
with more than 500 active 
research projects funded to the 
tune of $45 million in grants and 
run by 80 principal investigators 
—all from Yale. Those labs are 
currently conducting more than 
50 clinical trials.
The program includes several 
high-performing organizations. 
The Center for Neuroscience and 
Regeneration Research, headed 
by Stephen Waxman, MD, PhD, 
Bridget M. Flaherty Professor 
of Neurology, discovers ways 
to restore function in the ner-
vous system after injuries and 
strokes. The VA-Yale Clinical 
Neurosciences PTSD Research 
Program, headed by John 
Krystal, MD, Robert L. McNeil, 
Jr. Professor of Translational 
Research and professor of psy-
chiatry, and of neuroscience, 
seeks biological approaches to 
the treatment of trauma-related 
disorders. And the NIH-DoD-VA 
Pain Management Collaboratory 
Coordinating Center, run by 
Robert Kerns, PhD, professor of 
psychology, of neurology, and of 
psychiatry; Cynthia Brandt, MD, 
MPH, professor of emergency 
medicine and of anesthesiol-
ogy; and Peter Peduzzi, PhD, 
professor of biostatistics, helps 
guide clinical trials of nondrug 
approaches to pain management.
Yale faculty members who 
serve at the VA are dedicated to 
making life better for today’s 




and a glow-in-the-dark con-
ductor’s baton accompany 
an underscore set to creepy 
Halloween poetry readings. The 
2013 Halloween concert was a 
breakthrough moment for the 
group. “It opened everyone’s 
eyes that we were a real orches-
tra,” said Smith. “We’ve been 
packing the auditorium ever 
since.” To celebrate their 10th 
anniversary, Smith said, another 
Halloween concert is planned 
for October 27, with the winter 
concert on December 7.
The participating musicians 
come from all parts of Yale 
School of Medicine. In addition 
to faculty members and physi-
cians, the players include volun-
teers, students, and staff from 
many departments across the 
school as well as from Yale New 
Haven Hospital and the schools 
of Nursing and Public Health. 
“We could totally do this.” And 
the group was off and running: 
50 people from across the School 
of Medicine made the commit-
ment to rehearse and eventually 
perform as an orchestra. 
The symphony began regular 
weekly rehearsals in February 
2008, and at its first con-
cert, performed Beethoven’s 
Symphony No. 1. Two years later, 
Robert Smith, who had taken 
over Slywotzky’s position at 
the Hopkins School, joined the 
orchestra as conductor. Since 
those early days, the symphony 
has steadily moved on to more 
challenging works. At the May 
concert, the orchestra debuted 
its first Tchaikovsky symphony, 
No. 5, a piece, said Smith, that 
goes beyond the capacity of 
most similar orchestras. “They 
work so hard every week, even 
though they have pagers and 
are constantly attending their 
patients,” said Smith. 
YMSO plays two concerts a 
year: one in spring and another 
in winter. There are often spe-
cial concerts at Halloween. 
full house. Lynn Tanoue, MD, 
professor of medicine (pul-
monary), the group’s founder, 
started the orchestra after 
speaking with a school friend 
who, like Tanoue, is a musician. 
“We wouldn’t be here without 
Dr. Tanoue,” said Smith, as she 
was presented with flowers after 
the anniversary performance. 
Tanoue soon discovered that 
medical school orchestras are 
rare, but she found a supporter 
in Thomas Duffy, MD, profes-
sor emeritus of medicine, then 
the director of the School of 
Medicine’s Medical Humanities 
and the Arts Council. Duffy 
agreed to provide initial fund-
ing, and Tanoue reached out to 
the medical school community, 
seeking musicians who might be 
interested in playing together. 
Tanoue said 200 people 
responded, and she scheduled an 
open rehearsal where everyone 
would sight-read music together. 
Tanoue asked Adrian Slywotzky, 
director of instrumental music at 
the Hopkins School in New Haven 
at the time, to conduct the group. 
“That first night, all these 
people start showing up. It was 
unbelievable,” Tanoue said. 
“Adrian shows up with his arms 
full of music. [On the top] is 
Beethoven’s Fifth. I said, ‘Adrian, 
you don’t understand. We’re doc-
tors.’ He said, ‘No, no, it’s okay.’” 
That night, Tanoue sat in the 
Harkness balcony to listen to 
the newly assembled group play 
a piece by Rossini. They rose to 
Slywotzky’s challenge, she said. 
“Wow,” she remembers thinking. 
YMSO recruits musi-
cians from the School 
of Medicine and the 
broader medical  
community in New 
Haven. They’re held  


















Calamity struck in 
August, when over  
40 New Haven resi-
dents were poisoned 
on the Green by a 
synthetic cannabinoid. 
Doctors from Yale 
helped organize the 
response, while first-
responders treated 
victims on the scene.
For more on the poisoning, 
visit ymm.yale.edu/poison
“Music is the great equalizer. 
Your stand partner could be a 
famous scientist, or they could 
be a lab technician or a student,” 
said Tanoue. “The hierarchy that 
is so strong at the university and 
certainly in medicine totally 
disappears, so that nobody is 
more important than anybody 
else. No one is running that 
team except the conductor. And 
many of these people in their 
everyday lives are in charge of 
whatever they’re doing.”
“Medicine is all about relation-
ships and listening—with patients, 
with nurses, doctors, hospital 
staff, office staff, family members 
of patients,” said Anna Reisman, 
MD, associate professor of medi-
cine, director of the Program 
for Humanities in Medicine, 
and a symphony flutist. “You 
get nowhere if you’re not good 
at listening, which also means 
you have to be able to adapt your 
response depending on what’s 
said and how it’s said. The same 
thing happens in an orchestra.” 
To Smith, it’s no coincidence 
that people who spend their days 
steeped in science are also talented 
musicians. Much of the group per-
formed through high school and 
college, he said. Some were music 
majors as undergraduates or prin-
cipal chairs in their high school 
orchestras. “The idea of grasp-
ing for perfection, that kind of 
drive and work ethic serves both 
populations. It’s part of a person’s 
character to do these things at a 
high level and work hard at it. And 
in both, they are using their hands. 
It’s a technical application.” 
Aishwarya Singh, a 2014 
graduate of Yale College and cur-
rent second-year medical stu-
dent, nearly went to Julliard to 
pursue the violin but chose Yale 
College instead. She shares the 
first stand with Brian Rash, PhD, 
the orchestra’s concertmaster and 
an associate research scientist in 
neuroscience. “Music is one of 
those things when you are always 
learning, and medicine is like that 
too,” said Singh. “It’s not finite. 
That’s why I think, for a lot of 
people, both appeal to them. For 
a busy clinician it’s nice to have 
something that’s an escape.” 
Players connect at weekly 
rehearsals, in between concen-
trating on whatever piece they 
are working on. Graduate stu-
dents meet professors who might 
share their clinical interests; 
chamber music groups formed 
of orchestra members perform 
beyond the symphony. Smith 
said that there is little attrition 
from year to year, so the musi-
cians have come to know each 
other well and form a tight-knit 
community. “We come in and 
we have this joyful, hardworking 
time together,” Tanoue said. 
Going into its 11th year, the 
symphony is looking ahead to 
the future, and is seeking new 
ways to become sustainable, so 
that it can keep growing. As 
admission to its concerts is free, 
the symphony’s funding comes 
from grants and donations from 
its members. Money for the 
various incidentals required by 
a symphony, including equip-
ment, music, and support for the 
conductor wasn’t always easy 
to come by, but that changed 
recently. Thanks to an effort in 
spring of 2018 led by longtime 
music and YMSO fans Robert J. 
Alpern, MD, dean and Ensign 
Professor of Medicine and his 
wife, Patricia Preisig, PhD, pro-
fessor of medicine (nephrology), 
a $100,000 endowment was cre-
ated to pay the YMSO’s conduc-
tor a stipend. 
Retaining a professional 
musical visionary is a key com-
ponent of the symphony’s long-
term success, and guarantees 
that Yale’s medical community 
will continue to meet and con-
nect outside professional set-
tings. Alpern and Preisig’s 
efforts to institutionalize the 
conductor’s position will be a 
significant piece of their legacy.
“The conductors, we couldn’t 
function without them,” 
Tanoue said. “And both Adrian 
Slywotzky and Robert Smith 
have been amazing.”
Funds also mean YMSO can 
take on different projects like 
lecture series tied to perfor-
mances and concerts; the ability 
to bring music to patients’ bed-
sides; and children’s concerts. 
“The orchestra dreams big,” said 
Tanoue. “Why not?”
Smith said the group is ready 
to take on those big dreams. 
Musically, “I feel like we are 
where we need to be with the 
orchestra,” Smith said. They are 
ready to perform bigger, more 
iconic pieces for bigger audi-




If you think the depression of a spouse or 
loved one is making life sadder, you may 
be right. A recent study published in the 
American Journal of Geriatric Psychiatry, 
conducted by Yale researchers and their 
colleagues in Pittsburgh and Ann Arbor 
suggested a correlation between the two. 
Yale researchers have uncovered fascinat-
ing clues into the nature of human mem-
ory based on its mechanisms. Modules of 
cells can be triggered and recombined in 
the hippocampus, according to George 
Dragoi, MD, PhD, assistant professor of 
psychiatry and of neuroscience and senior 
author of the study published in Neuron 
in August. 
Molly Crockett, PhD, assistant professor 
of psychology, conducted a study with 
some counterintuitive conclusions about 
what we say versus what we prefer. Most 
people prefer to date or marry individuals 
who prioritize the good of their family and 
friends over strangers, which isn’t exactly 
altruistic. We want to feel good more 
than we want to be good.
ALL THE BEST ONES  
AREN’T TAKEN
ANOTHER DOWNSIDE  
TO DEPRESSION
MEMORY IN MODULES
Royal jelly might be more than just a stim-
ulant for bees to develop into royalty—it 
may provide clues into how cancer grows 
or how it dies. While research at Yale by 
Daryl Klein, MD, PhD, assistant professor 
of pharmacology, using jelly from China 
hasn’t yielded anything tangible yet, it can 
be spread on buttered wheat bread, but 
we wouldn’t recommend it. 
A REGAL HONEY
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a collection of recent  
scientific findings
IN THE 19 90 s, geneticists hoped that mapping the human genome would provide a 
path to treating many seemingly incurable or poorly understood conditions; obesity, de-
mentia, and cancer, to name a few. As understanding of genetics expanded and improved, 
however, scientists came to see the genome as just a first step in understanding a vastly 
more complex world of interactions within the body, one that extended to organisms that 
were not traditionally considered native or essential to humans—the microbiome.
Research at Yale focuses on a wide swath of relationships between microbes and 
humans, from the gut to DNA. According to the latest inquiries, the evolution of Homo 
sapiens is not just a tale of vertebrate mutations, in which genetic variation leads to useful 
adaptation, but a hyper-complex series of mutually beneficial arrangements between the 
human body and the many organisms that call it home.
In some cases, researchers are still attempting to establish a correlation between a 
given microbe and conditions in humans. This issue explores some of those possibilities in 
articles about diabetes, cystic fibrosis, and multiple sclerosis. In other cases where a cor-
relation has been established, such as with Clostridium difficile infections, the question is 
not whether microbes play a role in human health, but the specific nature of that role.
One fact has become apparent in compiling this issue of Yale Medicine Magazine: 
the old idea of the human body as a self-sufficient entity constantly fighting hostile mi-
crobes is obsolete. We are collections of organisms working together to survive.  
At least on a cellular level, the concept of the heroic individual is not just anomalous—it is 
absurd, unworkable. Each person is a miracle of cooperation and altruistic mutual interest, 
a collective of creatures. Good health and evolutionary success are the products of  
alliances, not ruthless selfish competition.
A sophisticated system 12
Mysterious medicine 20
Infection control 22
Costs and benefits 26
From bench to book 28
Good bugs gone bad 32
Evolving attitudes 34
An end to dieting 38
Go with your gut





















The microbiome: helping keep bodies healthy
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How researchers at Yale are complicating 
the picture of human health.
A long struggle with Clostridium 
difficile left Jane Norgren weak 
and emotionally despondent— 
until she underwent a revolution-
ary new therapy. Cured of the 
infection, she’s eager to share her 




Then Norgren’s agony was over. That’s because she was 
one of the first people in Connecticut to benefit from 
fecal microbiota transplantation (FMT). Most of the 
existing bacteria in her digestive tract were killed by a 
heavy dose of antibiotics and replaced by healthy bac-
teria from a fecal donor (her daughter). “I have been 
fine ever since,” she says.
The procedure was performed by Paul Feuerstadt, 
MD, an assistant clinical professor of medicine at Yale 
School of Medicine. He says that more than 95 percent 
of the patients he has treated in this way through the 
Gastroenterology Center of Connecticut have recovered. 
FMT is the first treatment that has emerged from a 
wave of research on the role of the microbiome in health. 
For years, most medical researchers treated microbes as 
a sideshow to the main event—the role of genetics in ill-
ness and medicine. Now, many are turning their atten-
tion to the impact on health of the trillions of bacteria, 
fungi, and other tiny organisms that colonize human 
digestive systems, lungs, nasal passages, skin, vaginas, 
and many other body parts and surfaces. 
“For medical science, this is our next frontier. The 
better we understand our microbiome, the better we’ll 
be able to potentially avoid diseases or treat them more 
successfully,” says Feuerstadt.
Researchers believe that the microbiome plays a role 
in a wide variety of human diseases and conditions, 
including inflammatory bowel disease, irritable bowel 
syndrome, Crohn’s disease, lupus, chronic fatigue syn-
drome, fibromyalgia, cardiovascular disease, cancer, 
Parkinson’s, diabetes, cystic fibrosis, asthma, autism, 
and some forms of mental illness. 
At Yale School of Medicine, researchers from more 
than a dozen academic departments are studying the 
microbiome. Some focus on understanding the fundamen-
tal mechanisms whereby bacteria interact with each other 
and with our bodies. Others develop tools for sequencing 
and editing genes in bacteria. Still others are focusing on 
the effects of the microbiome on specific diseases. 
While these are early days, it’s already clear that 
Yale researchers are playing a key role in the microbi-
ome revolution. For instance, Loren Laine, MD, pro-
fessor of medicine and interim chief of the Section of 
Digestive Diseases, was instrumental in establishing 
the American Gastroenterological Association’s Fecal 
Microbiota Transplantation National Registry, which 
helps researchers assess short- and long-term out-
comes associated with FMT.
This wave of microbiome research has been gather-
ing strength for about a decade. However, the history 
of such research began in the 1860s when the French 
chemist Louis Pasteur showed that microbes are pres-
ent all around us and in our bodies, and that some are 
responsible for diseases. Ever since, medical scientists 
have been studying the microbiota in the environment, 
animals, and humans so that physicians can better 
combat infection. With the emergence of antibiotics in 
the 1930s and 1940s, many believed that infectious dis-
eases would swiftly be eliminated. Sadly, it didn’t hap-
pen. Now, resistance to antibiotics is a major concern.
Until a little over a decade ago, most research on the 
microbiome focused on which microbes played a role 
in causing infectious diseases, and how. Then came 
the Human Genome Project (HGP), launched in 1990 
and completed in 2003, which provided the foundation 
of a better understanding of the genetic basis of such 
diseases as cancer. It was discovered that genes alone 
were often not sufficient to fully explain why complex 
Jane Norgren was suffering terribly. A pernicious bacterium, 
Clostridium difficile, had taken up residence in her colon 
and refused to leave—no matter what antibiotics she took. 
As a result, she had bouts of uncontrollable diarrhea on 
and off for nearly four years. It was a miserable situation. 
She always had to be near a bathroom. “I felt like I was 






















After screening over 1,000 non-antibiotic  
drugs against 40 gut bacterial strains, 
researchers found that several classes—par-
ticularly antipsychotics—prevented healthy 
microbes from thriving. The findings suggest 
that these drugs could influence neurological 
diseases via microbial interactions. However, 
the study’s in vitro design is a limiting factor. 
Lungs 
Microbial communities in our gut might 
increase the likelihood of developing asthma. 
Infants with higher levels of the fungi Candida 
and Rhodotorula in their gut, detected  
through stool samples, were more likely to  
be diagnosed with asthma at age 4. 
Eyes 
The pathogenesis of glaucoma, the most com-
mon cause of blindness worldwide, remains 
unclear. Researchers know that high intraocular 
pressure (IOP) and overactive immune T-cells 
play key roles. A study earlier this year hints 
that limiting bacterial strains in the ocular 
microbiome might also be a factor. Mice with 
fewer ocular microflora strains experienced 
less IOP-related damage compared to those 
with more. 
Pancreas
Intermittent fasting might help alleviate  
vision loss, called diabetic retinopathy, in  
diabetic mice. This phenomenon could be due 
to restructured gut microbiota. Mice who 
fasted on alternate days had an increase  
in a chemical chaperone called tauroursode-
oxycholic acid, which has been shown to  
slow retinal degeneration. 
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diseases occur or how therapies work. So researchers 
began to look more deeply into the genetic makeup of 
microbes and their interactions with each other and 
with human cells—both negative and positive.
In an effort reminiscent of the HGP, the U.S. 
National Institutes of Health in 2007 launched the 
Human Microbiome Project. The goal was to fund 
research and collect data about the genomes and 
interactions of all the microorganisms in or on our 
bodies. Research funded by the project provides 
today’s scientists with a trove of data upon which to 
base their new inquiries. 
One factor that makes this research so complex is 
that no two people have the same microbiome. While 
broad commonalities exist, each human has his or 
her own stew of bacteria and other organisms. In 
addition, while our personal microbiomes tend to be 
relatively stable, they change with the introduction of 
new organisms from the environment. So my microbes 
interact with my body differently than yours do with 
your body; and they interact differently today than 
they did six months ago.
And consider this: There are 150 times more genes 
in our microbiome than in our genome.
Yale faculty members say this complexity must be 
overcome. The ability to sequence and map human 
genomes has raised hopes that physicians will be able 
to understand an individual’s body so well that they 
can deliver truly personalized medicine—custom-
designed therapies and treatments that will work espe-
cially well for that individual. Yet it’s becoming clear 
that understanding human genes and cells won’t be 
enough. “To truly understand the signals that regulate 
the expression of both healthy and diseased genes, you 
need to understand the microbiome. Precision medicine 
will be fairly imprecise without this,” says Gary Desir, 
MD, the Paul B. Beeson Professor of Medicine and chair 
of Internal Medicine. 
Scientists admit they are still at the beginning 
stages of understanding the role of the microbiome in 
health. “We aren’t yet at the point where we can look 
at what is there in a microbiome and tell you much 
about what it can do. It’s hard to identify a diseased 
microbiome if you don’t know what a healthy one is,” 
says Andrew Goodman, PhD, an associate professor of 
microbial pathogenesis.
Goodman is determined to change that. His 
lab on Yale West Campus focuses on deepening 
A sophisticated system
  Martin Kriegel
 “This may become personalized medicine.  
  We need to look at … human genes,  
 and at the microbiome in the patient’s gut  
  and tissues. Based on these analyses, we 
should be able to decide on the best treatment  
  for a particular patient in the future. 
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understanding of how microbes in our digestive 
systems, the so-called gut microbiome, interact 
with each other and us. He and his colleagues have 
seen situations in which one microbe species uses a 
vitamin produced by another to survive in the gut; 
and others in which microbes fight each other to 
the death. On the microbe-to-host axis, the team is 
learning how gut microbes could affect how particu-
lar individuals respond to particular drugs. 
So far, most of this experimentation involves mice—
but not just any mice: germ-free mice. Only by using 
mice with no bacteria present can researchers introduce 
individual species or consortia of microbes and study the 
effects of their absence or presence. Although Goodman 
has a dedicated team of experts in these techniques, the 
med school also has a central germ-free mouse facility 
that all the scientists can access.
Another essential element of microbiome research is 
the tools that are used to read and analyze the genetic 
code within microbes and then to edit or even recode 
their DNA so that they interact with each other and 
our bodies in different ways. 
Scientists employ the same tools for microbes that 
are used for human genetics research. The CRISPR/Cas9 
technology has democratized gene editing by enabling 
scientists to cut and paste snippets of DNA code rela-
tively easily. But researchers at Yale are some of the 
leaders in developing new approaches that don’t involve 
breaking the double strands of DNA and killing cells.
One effort is led by Farren Isaacs, PhD, an associ-
ate professor of molecular, cellular and developmental 
biology. His lab produces and uses high-throughput 
gene engineering technologies. With these tools, the 
researchers can rewrite the genomes of human cells 
and bacteria on a large scale—introducing scores of 
precise edits without creating double-stranded breaks 
in the strings of genes. His team developed a tech-
nique called eukaryotic multiplex genome engineering 
(eMAGE) and used it to alter the genetic information 
in yeast. The team members hope this technique will 
be used eventually to alter disease-causing genes in 
human cells and microbes.
Earlier this year, Isaacs’ lab pitched in on an effort 
aimed at engineering communities of gut microbes 
to help humans digest cellobiose, one of the most 
abundant disaccharides present in vegetables, which 
our digestive systems don’t have the means to metabo-
lize. If efforts like this pay off, we will be able to har-
vest more energy from the food we eat.
Across the spectrum of Yale academic depart-
ments, researchers are using germ-free mice and gene 
sequencing and editing tools to advance research on 
the role of the microbiome in a wide variety of dis-
eases and body functions. Laypeople tend to think that 
bacteria in the digestive system stays put, but in fact, 
microbes migrate via the blood to a host of other body 
organs and systems, including the liver, the lymph 
nodes, and even the brain. Much of the research focus 
at Yale is on infectious diseases, the immune system, 
and autoimmune diseases. 
Martin Kriegel, MD, PhD, FW ’06, adjunct assistant 
professor of immunobiology, and of medicine (rheumatol-
ogy), has been focusing on Enterococcus gallinarum, a 
bacterium that his team discovered can migrate from 
the gut into the lymph nodes, liver, and spleen in predis-
posed hosts—thereby producing an autoimmune response. 
Kriegel’s research team found that they could suppress the 
response caused by E. gallinarum in mice with an antibi-
otic or vaccine. Research like this could help pharmaceuti-
cal companies produce antibiotics and vaccines that are 
particularly good at attacking specific bacteria.
“This may become personalized medicine,” says 
Kriegel. “We need to look at the host predisposition 
such as the human genes, and at the microbiome in 
the patient’s gut and tissues. Based on these analyses, 
we should be able to decide on the best treatment for a 
particular patient in the future.”
Other labs are focusing on prevention in addition 
to cures. Li Wen, MD, PhD, FW ’97, associate pro-
fessor of medicine (endocrinology), is looking into 
the causes of type 1 and type 2 diabetes. Her team’s 
research has shown that certain types of gut bacteria 
cause intestinal inflammation, which in turn pro-
motes the development of type 1 diabetes. At the same 
time, the research shows that obesity and other fac-
tors associated with type 2 diabetes are more prevalent 
in patients with low diversity in the gut microbiome. 
Down the road, she believes, people with a genetic 
predisposition to diabetes may be able to fend off the 
disease by consuming customized probiotic cocktails.
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  Shari Hoffman
 “This makes me optimistic that  
   patients may one day receive better  
 care and have better overall well-being. 
A sophisticated system
“I think prevention is most important,” she says. 
“It’s the most effective and economical way to deal  
with diabetes.” 
While most of the research at Yale concerns the gut 
microbiome, a handful of faculty members are focusing 
on other body parts or systems. For instance, Barbara 
Kazmierczak, MD, PhD, a professor of medicine and of 
microbial pathogenesis, specializes in the lung microbi-
ome—specifically the effects of bacteria on cystic fibrosis. 
Much of the research being done at Yale, while 
promising, is not expected to deliver new treatments 
or drugs for many years. But some projects might be 
closer to the marketplace. For instance, two profes-
sors—Noah Palm, PhD, assistant professor of immuno-
biology, and Richard Flavell, PhD, Sterling Professor of 
Immunobiology—are co-founders of a startup company 
Artizan Biosciences, aimed at identifying harmful 
bacteria in the gut and targeting them for destruction. 
One of their first targets: inflammatory bowel disease.
“We found that when we take a healthy microbiota and 
add one microbe to the mixture, the mouse gets sick. On 
the flip side, if you’re able to block the pathologic effects 
of that bug or eliminate it entirely, the mouse does not 
get sick,” says Palm. The next step is figuring out how to 
attack the bad bug—with targeted antibiotics, small mol-
ecules, or perhaps even phages.
Elsewhere around the country, a number of medi-
cal schools are establishing major research initia-
tives focused on the microbiome. Among them are 
Harvard, University of Chicago, Stanford, University 
of Pittsburgh, University of Michigan, and New  
York University. 
Several Yale researchers say they’d like to see a 
larger and more coordinated effort to foster and sup-
port microbiome research. Such an initiative might 
make it easier for them to secure funding and develop 
more multidisciplinary collaborations. Moreover, there 
would likely be benefits from expanding the variety 
of research done at Yale. Right now, most of the focus 
is on experimental science and the gut microbiome. 
They’d like to see more done in data analysis and in 
other microbiomes.
Goodman, who on his own keeps a web page  
(medicine.yale.edu/microbiomeresearch) tracking 
microbiome research at Yale, says, “I’d like to see it 
happen. There’s a such a great base of people here. 
There’s a lot of opportunity for really exciting things 
with more coordination and resources.” 
Meanwhile, local people who suffer from diseases 
related to the microbiome are cheering Yale researchers  
on. One of them, Shari Hoffman of New Haven, says, 
“This makes me optimistic that patients may one day 
receive better care and have better overall well-being.”  
/yale medicine magazine






















Young people who suffer from Crohn’s disease 
(CD), a chronic inflammatory bowel disease, 
have reduced levels of beneficial bacteria in their 
intestines, according to an oft-cited 2014 study 
published in Cell Host & Microbe. Researchers 
sequenced the genome of microbes in tissue 
samples taken from the large intestine and 
from fecal samples of about 600 children and 
adolescents. None of the patients had received 
treatment—usually antibiotics—for CD just yet. 
The researchers pointed to the likely further 
harm that antibiotics might wreak on their gut. 
Muscles 
Microbes in the gut that are often found in peo-
ple with multiple sclerosis (MS) appear to change 
how white blood cells interact with the body’s 
cells—including neurons—by making them more 
likely to attack, according to a study that used 
mouse models. Another study found that when 
researchers implanted gut bacteria from humans 
with MS into mice, those animals were more likely 
to develop the autoimmune disease. 
Colon 
Fecal microbiota transplantation (FMT), known 
colloquially as a “poop pill,” is the only microbiome- 
related therapy that has been studied extensive-
ly in clinical trials. It is an established effective 
treatment for difficult-to-treat or recurrent 
Clostridium difficile infections. 
Knees 
Gut microbes may influence the adaptive im-
mune response, which goes awry in autoim-
mune diseases like rheumatoid arthritis (RA). 
In a small 2016 study, RA patients appeared to 
have decreased gut microbial diversity and large 
numbers of Collinsella bacteria, according to a 
DNA analysis of stool samples. 
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Take a look up and down the supermarket aisles: probi-
otics, loaded with the “good bacteria” once relegated to 
yogurt and a few other fermented foods such as kimchi 
and pickles, have escaped the dairy cases. They appear 
in packaged foods now, with cereals, snacks, and even 
chocolate infused with these good bugs. Studies of the 
microbiome have provided an unintended boost to the 
market for probiotics, shedding light on their power and 
revealing some potential for therapeutic use beyond an 
occasional yogurt to boost digestion. 
Though probiotics have become a multimillion-
dollar cottage industry, much of the science behind 
them remains murky. “The idea certainly has scientific 
merit,” says Ruslan Medzhitov, PhD, Sterling Professor 
of Immunobiology and a Howard Hughes Medical Insti-
tute investigator whose lab studies the microbiome’s 
impact on diet and inflammation. “But the vast major-
ity of claims surrounding probiotics are based on very 
loose connections and correlations. This is not to say 
that the idea is wrong, just that we don’t know enough 
about the biology of commensal bacteria to start using 
them in this wholesale manner.” 
Still, those correlations are strong enough that 
probiotics are beginning a transition from general food 
supplements to medically valid treatments for serious 
diseases. Priti Kumar, PhD, associate professor of infec-
tious diseases, is examining a role for probiotics in HIV 
treatment. One question that has long frustrated HIV 
researchers is why HIV patients on a successful regimen 
of antiretroviral therapy (ART) exhibit signs of early 
immunosenescence. Evidence, Kumar says, points to a 
change in the composition of the gut microbiome. Could 
probiotics be used to halt or reverse the premature ag-
ing process? Recent studies have examined introducing 
the bacterial genus Lactobacillus, which is commonly 
found in yogurt and other over-the-counter probiot-
ics, into the diet of HIV patients. “Just introducing this 
single probiotic strain in the diet seems to really make 
a marked improvement, in bringing the immune system 
several steps toward normalcy,” Kumar says.
While a potential success, this novel therapy 
also highlights a limitation of the use of probiotics as 
therapy. To maintain their healthy status, HIV patients 
must take ART for the rest of their lives. Probiotics 
must be used in the same way, because most of these 
mysterious 
medicine
Research shows that probiotics 
can treat some ailments,  
but has not yet shown why.
by jeanna lucci-canapari
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good bugs have not evolved to adhere to the gut, and 
they end up passing through the body very quickly. 
This finding poses another interesting question: “If 
something is good for us, then why didn’t we evolve to 
hold on to it?” asks Medzhitov. “We are holding on to 
trillions of bacteria. Why are we not holding on to oth-
ers that are good for us?” 
Evolution may provide the answer. A recent finding 
revealed that some “bad” bacteria in the gut microbi-
ome can promote obesity, which can lead to such meta-
bolic diseases as type 2 diabetes, while other so-called 
“good” bacteria are associated with lean individuals. 
“One is good and one is bad,” says Medzhitov. 
“However, what we define as good and bad can be dif-
ferent than what would have been considered good 
and bad in our evolutionary ancestors.” This observa-
tion can explain why so-called “good bacteria” are not 
stable in the human intestines. “From an evolutionary 
perspective, there is nothing good about them. They 
make you lean,” says Medzhitov. “That’s good if you 
are in Hollywood, but not if you are a caveman that 
can only eat every three days.” Because human genes 
have not had the time to adjust to the drastic changes 
in modern life that have occurred only in the last few 
hundred years, including modern medicine, hygiene, 
and obesity-causing food abundance, they still operate 
under the assumption that what are now considered 
bad bacteria are actually good, and vice versa. 
Medzhitov predicts that in the next 10 to 15 years, 
probiotics will make the leap to synthetic biology, 
which would incorporate engineering and gene modi-
fication in their design. “Once we know enough about 
how bacteria in the gut adapt to their environment, 
understanding what makes them stable or unstable in 
the host, or what makes them good or bad, and apply 
the tools of synthetic biology, which are increasingly 
sophisticated, one could theoretically create ‘designer 
probiotics,’ where we could introduce genes that en-
code specific proteins that would metabolize certain 
toxins, for example,” he says. 
This novel approach to probiotics would still have 
to pass muster with public opinion. Just as there is 
strong support for natural commercially available 
probiotics at the moment, there is powerful opposition 
to genetically modified organisms (GMOs) in food. Yet 
many of these next-generation probiotics by definition 
must be genetically modified. Jason Crawford, PhD, the 
Maxine F. Singer ’57 PhD Associate Professor of Chem-
istry and associate professor of microbial pathogenesis, 
cites an example of a probiotic he is working on that has 
the potential to prevent colorectal cancer. “The chal-
lenges for this example are in the regulatory landscape, 
not the science,” he says. “A neutralizing enzyme that 
we discovered protects humans from a particular toxin, 
but it needs to be secreted outside the cell as opposed 
to inside the cell. We need to change that single gene to 
have a secretion signal. But we can’t easily do that with 
the current regulatory landscape. As soon as we modify 
that organism, then it’s a GMO. That is a huge current 
barrier between research science and market potential.”
Over-the-counter probiotics are not regulated  
by the Food and Drug Administration. Because other 
next-generation probiotics will be labeled as GMOs, 
“it’s a different story,” says Medzhitov. “There is an 
assumption that if they are genetically modified, there 
is something unnatural about them, as if all of evolu-
tion is not about genetic modification. Bugs exchange 
genes all the time, they are always being genetically 
modified. There is nothing unnatural about it.”
As with all other discoveries, these probiotics of the 
future “would suffer from a certain amount of suspi-
cion,” says Medzhitov. “But over time, science will win.”






by carrie macmillan | robert lisak photographs
A dangerous hospital-acquired  
infection, Clostridium difficile, is now  
increasing in the community.
Marianne J. Davies, assistant 
professor of nursing at Yale 
School of Nursing, is familiar with 
Clostridium difficile (C. diff).  
She describes a healthy immune 
system as “checks and balances” 
and C. diff infections as opportu-
nistic, occurring when already-
weakened immune systems are 
thrown out of balance from,  
for example, prolonged antibiotic 




In a perfect world, beneficial bugs in the microbiome 
keep the bad ones in check. But when normal bacteria 
are wiped out (most often by antibiotics or illness), C. diff 
flourishes and can cause a brutal infection characterized 
by violent, uncontrollable diarrhea. Sometimes, espe-
cially in frail, very sick patients, this infection leads to 
serious complications, even death. 
“If there is a window to overtake a healthy environ-
ment, C. diff will find it,” says Marianne J. Davies, DNP, 
APRN, an assistant professor of nursing at Yale School of 
Nursing. “The normal bacteria in your bowel maintain 
metabolism, break down food, and help with digestion. 
When you take antibiotics, you lower the normal flora 
that keep other pathogens out of the body. It’s like rou-
tine checks and balances.”
C. diff is the most common health care-associated 
infection in the United States, causing approximately 
500,000 infections and 29,000 deaths in 2015, according 
to the Centers for Disease Control and Prevention (CDC). 
And recently, for reasons researchers don’t under-
stand, C. diff infections acquired in the community 
(versus hospitals, where the rate is actually decreasing) 
have been on the rise. 
“There are theories as to why this is happening. Are 
we seeing more aggressive or resistant strains because 
facilities have become more efficient and are discharg-
ing patients before C. diff has had an opportunity to 
demonstrate itself?” Davies asks. “Typically, the onset 
is after you’ve been on antibiotics for five to 10 days.”
Preventive initiatives, such as limiting the use of 
antibiotics unless truly necessary, are imperative, Yale 
experts say. 
NATURE’S BOUNTY
Commonly found in the air, soil, and water, C. diff is a 
bacterium that occurs naturally in the gut microbiome 
of about 5 percent of the population. But that doesn’t 
make it benign.
“Healthy people with a hearty immune system  
may have C. diff in their intestinal tract, and they co-
exist with it,” Davies says, noting, “But it’s not what 
we call normal flora.” 
For patients in a health care setting, recent antibi-
otic use is the leading risk factor for contracting a C. diff 
infection. People on antibiotics are seven to 10 times more 
likely to get C. diff while on the medications and dur-
ing the month after, the CDC reports. Antibiotics, which 
destroy and slow the growth of harmful germs, end up 
killing the good bugs too, explains Laura K. Andrews, 
PhD, APRN, an associate professor of nursing at Yale 
School of Nursing. This blanket effect gives C. diff room 
to multiply and crowd out any normal bugs that remain. 
Once entrenched, C. diff releases toxins that 
inflame the protective lining of the large intestine. This 
causes C. diff colitis, which entails up to 30 watery 
stools a day, along with abdominal pain and fever. 
“A mild case might mean taking oral antibiotics at 
home to treat it. For severe to life-threatening cases, 
you end up in the ICU and can even go into shock with 
multisystem organ failure,” Andrews says. “Patients 
can become profoundly dehydrated in less than 
24 hours. They are losing liters of fluid.” 
Other high-risk factors for C. diff infection include 
being over age 65 and/or taking immune-suppressing 
medications. Adding further challenges, C. diff can 
survive for months, is resistant to disinfectants, and can 
spread after contact with any contaminated surface. 
“When you walk through a hospital, you see Purell 
and other alcohol-based sanitizers all over. These are 
a good reminder to staff and visitors that handwash-
ing is important. Which is great, but these products are 
just an extra step. They will not kill C. diff spores. For 
In the messy world of the gastrointestinal tract, good and evil 
can, at least temporarily, coexist. The gut is home to trillions  
of bacteria, fungi, viruses, and parasites. Most are helpful  
in obscure ways, assisting the body in carrying out its various 
vital functions. But some types of bacteria, including Clostridium 
difficile (C. diff ), are nefarious and opportunistic.
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that, she explains “diligent handwashing with hot soapy 
water is essential.” It takes bleach to kill the spores on 
surfaces and the friction of handwashing to rid hands of 
C. diff.
HAIR OF THE DOG
Fortunately, many infections respond to treatment 
with antibiotics. Typically, it takes a 10-day course, 
but some people may require more time or a course of 
IV antibiotics in a hospital. 
“If you are harboring bacteria in your bowel, there 
is risk of recurring infection, so it’s important to fol-
low the prescribed course of antibiotics. Discontinuing 
antibiotics when symptoms decrease can contribute to 
antibiotic resistance,” Davies says.
Serious or resistant C. diff infections may require 
more aggressive strategies. In some cases, a fecal trans-
plant procedure (transferring bacteria from a healthy 
person’s colon) may be necessary. For instance, surgery 
may be required to fix a perforated colon.
“Some strains are resistant to antibiotics, which is 
why we caution people not to self-medicate with anti-
biotics just because you have them,” Davies says. “We, 
as medical professionals, are making concerted efforts 
to be good antibiotic stewards and not overprescribe, 
to minimize resistance to any strain.” 
Andrews agrees. “People get a cold and often go to 
the doctor demanding antibiotics, but a cold is a virus 
and antibiotics won’t work. Taking them unnecessar-
ily is causing virulence and resistance in many classes 
of microbes,” she says. “By doing this, you are going to 
cause resistance five or 10 years down the line.” 
Researchers believe a particularly virulent strain of 
C. diff—NAP1—that emerged in 2000 was spawned by 
antibiotic overuse. This strain accounts for about 30 per-
cent of all C. diff cases. “It’s a big toxin producer. It can also 
be antibiotic-resistant and tends to recur,” Andrews says. 
Furthermore, there has been a slow rise of commu-
nity cases, including those among people who don’t fit 
the mold. “We are seeing it in a younger population,  
in those who aren’t immune-suppressed,” Davies says. 
“If a 19-year-old who is not on antibiotics or immune-
suppressing medications comes into my office  
with significant diarrhea, C. diff is still something  
to think about.” 
Yale School of Public Health is part of the Connecticut  
Emerging Infections Program, a collaboration between 
the Connecticut State Department of Public Health and 
the CDC. Its C. difficile surveillance program moni-
tors all cases in New Haven County and is one of 10 sites 
throughout the United States monitoring C. diff infec-
tions in the population.
“One of the biggest trends we are looking at is from 
2011 to 2017, when we saw the overall number of C. diff 
cases, as well as the hospital-acquired cases, go down. 
But the community-associated cases were going up,” 
says Danyel Olson, MS, MPH, the program’s surveil-
lance coordinator. That trend continued until about 
2015, Olson says, when the rates stabilized. 
“The decrease in hospital infections could be from 
implementation of infection control practices, anti-
biotic stewardship, and new treatment guidelines,” 
Olson says. “We are unsure why infections increased 
in the community.”
Andrews, for one, is optimistic about the tide turn-
ing when it comes to the overuse of antibiotics. “I think 
half the battle is recognizing that this is a problem,” she 
says. “C. diff infection rates may get worse before they 
get better, but I think it goes back to getting antibiotic 
prescriptions under control.” /yale medicine magazine
Carrie MacMillan is a staff writer for Yale Medicine, the clinical prac-
tice of Yale School of Medicine.
Awareness of the threat posed 
by C. diff and similar infections 
has led to changes in prescription 
habits and that’s a good thing, 
says Laura Kierol Andrews.
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Hookworm, one of humankind’s oldest foes, dwells in 
the ground, waiting quietly for its victims. This gape-
mouthed parasite gains entry from warm, moist soils 
through bare feet; takes a trip through the lungs; and 
settles in the intestine to suck blood, often causing 
anemia, malnutrition, and stunted development. More 
than 500 million people worldwide are thought to be 
infected, mostly in Latin America, Africa, and South-
east Asia, and vaccination development and deworm-
ing solutions are underway. 
But the hookworm and related parasitic worms, 
called helminths, may also have something to offer 
us. Infection can be protective in some circumstances, 
and Yale researchers are finding that the creatures can 
teach us how our immune systems self-regulate. 
“These parasites have evolved over hundreds of 
thousands of years with their mammalian host.  
They understand each other extremely well,” says 
Michael Cappello, MD, a professor of pediatrics, of 
microbial pathogenesis, and of public health, who  
studies how nutrition influences susceptibility to 
worm infection, as well as the efficacy—or lack  
thereof—of treatment. 
The human-worm relationship may be an agree-
ment of sorts, Cappello suggests. “ ‘We’ll allow you in 
as long as you don’t cause too much disease and you 
don’t overwhelm us,’ ” he says, adding, “I think that we 
have evolved to harbor light worm infections.” 
As evidence, Cappello explains that curing worm 
infections may not necessarily make a child healthier: 
“In some places, [mass deworming] has brought down 
the intensity of worm infections. But it’s been less 
clear that those reductions are actually associated 
with improved health.” 
The worm might protect children from some of the 
worst effects of malaria. In 2007, Cappello studied ane-
mia levels in Ghanaian children who were infected with 
malaria, hookworm, both, or neither. Having either 
one of the two infections rendered a child more likely 
to be anemic compared to uninfected children. With 
malaria, the anemia was especially severe. Paradoxi-
cally, though, having both infections at once does not 
multiply that likelihood, the team found. In fact, having 
both parasites resulted in less severe anemia than in 
victims suffering from just malaria.
by jenny blair, md ’04
Costs and 
benefits
Some parasites may be unlikely 
allies with human health.
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“The combination of these two parasitic diseases is 
such that they actually in some ways kind of cancel each 
other out—and it may be that light hookworm infection 
blunts the response to malaria that leads to anemia,” 
Cappello says. “This was a surprising finding. … but  
it does add some supporting evidence to the idea that 
light worm infections may be beneficial.”
To be clear, that’s light infection. Moderate and 
heavy infections seem to do more harm than good, so 
it’s important to keep the worm under control. One 
major tool for doing this is mass drug administration, 
or deworming people en masse with a single dose of 
an antiparasitic drug like albendazole. But while this 
approach has been shown to reduce the prevalence of 
worm infections in some parts of the world, it doesn’t 
always work as expected. 
In West Africa, for instance, Cappello’s team has 
found that mass drug administration has spotty efficacy. 
“Some villages have a cure rate with albendazole 
that is 75 percent, whereas a few miles away a village 
showed a cure rate of zero,” Cappello says. The reasons 
have to do with the child’s nutritional status, the tim-
ing of treatment, and some worms’ genetic resistance 
to the drug, he believes. 
So current worm control strategies may need to 
evolve, and Cappello wants to be ready. “Our lab and a 
small number of other groups around the world are try-
ing to develop tools so that resistance can be detected 
when it emerges,” he says. 
Hookworms are also chemistry wizards of sorts, 
manufacturing molecules that lead to profound effects 
in their hosts. They pump out anti-clotting molecules, 
for example, to keep their blood meals flowing (Cap-
pello spent his early career purifying these molecules, 
one of which made it to human drug trials). 
Perhaps more importantly, the worms also send 
molecular communications that regulate the immune 
system and ward off a strong attack. Carla Rothlin, 
PhD, is an associate professor of immunobiology and 
of pharmacology, who studies the immune system’s 
brakes—which molecules and pathways signal that it’s 
time to slow or stop an immune attack. One such brake 
is called the TAM receptor. The body can stimulate 
that receptor itself, but parasites can do it too. During 
an immune response to helminth infection, Rothlin’s 
lab has found that immune cells begin making massive 
amounts of a molecule called IL-4. That leads to the 
creation of a molecule called protein S, which plugs 
into TAM receptors and starts a negative feedback 
loop that calms the immune system.
Piecing together interactions like this one may 
shed light on the hygiene hypothesis—a way of explain-
ing why, as sanitation improves and people are ex-
posed to fewer microorganisms, their rates of allergy 
and autoimmune diseases go up. Researchers believe 
the immune system has evolved to anticipate its para-
sitic foes and even to rely on their tools for tamping 
down the immune system. When the parasite and its 
moderating influence are absent, we turn on ourselves. 
This is the idea behind helminth therapy, in which 
worms are deliberately ingested to treat autoim-
mune and allergic diseases. Pig whipworm eggs have 
been studied as a treatment for inflammatory bowel 
disease, for example. Unable to develop to adulthood 
in humans, the eggs nonetheless deliver molecular 
messages to the human immune system that seem 
to curtail its propensity to attack itself. Intentional 
hookworm infections have also been investigated for 
allergic rhinitis.
But Rothlin believes it may be safer to pinpoint 
which molecules the worms use to talk to the immune 
system, then mimic that communication with drugs. 
This approach could replace potentially risky experi-
ments with parasite infection—a practice “I would 
argue … can be very dangerous,” Rothlin says. 
“Microorganisms are very good at this,” she adds. 
“For millions and millions of years, they have tried to usurp 
the regulatory pathways that we have. We can now study 
them, identify which molecules [they use, and] know 
more about the regulatory pathway itself. Microorgan-
isms are great tools to understand immunology.”
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From bench  
to book
How research findings make their 
way to the classroom.
Yale School of Medicine’s Rich-
ard Belitsky, left, and Michael 
Schwartz work with faculty to 
shepherd the latest medical re-
search from the pages of publica-
tions into the school’s curriculum.
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One lecture covers “what the microbiome is known to 
do in the health and disease setting, everything from 
Alzheimer’s to autism to obesity to cancer. It’s a very 
broad stroke—there aren’t enough lecture hours to 
get into specific areas,” said Akiko Iwasaki, PhD, the 
Waldemar Von Zedtwitz Professor of Immunobiology, 
and Molecular, Cellular, and Developmental Biology, and 
a Howard Hughes Medical Institute investigator. “There’s 
so much discovery going on in the microbiome field. I 
believe it’s going to have to be expanded every year.”
The new medical school curriculum, unveiled in  
the fall of 2015, anticipated exactly this kind of scien-
tific advance. 
“No matter what we define as the content of the 
curriculum, no matter what we decide to teach at any 
given point in time, as we are planning and imple-
menting the curriculum, knowledge is continually 
changing,” said Richard Belitsky, MD, HS ’82, FW ’83, 
deputy dean for education, the Harold W. Jockers 
Associate Professor of Medical Education, and associate 
professor of psychiatry.
With each advance, faculty and administrators 
gauge the breakthrough’s importance and whether it’s 
something medical students need to know. For each 
new finding, faculty must figure out how and who to 
teach it, and—there are only so many hours in the day—
find space in the curriculum. “People who are teaching 
are always thinking about this,” Belitsky said. “We rely 
on the expertise of our faculty to determine the key 
things our students need to know. We ask them to do it 
not independently of the curriculum, but coordinated 
with the rest of the curriculum.”
Belitsky jokes that managing this constant pressure 
on medical education explains the large bottle of Tums 
on the desk of Michael L. Schwartz, PhD, associate 
professor of neuroscience and associate dean for cur-
riculum. It falls to Schwartz to work such discoveries 
into the classroom. This integration happens in two 
ways, Schwartz said, the first of which involves fac-
ulty keeping tabs on what’s happening in the various 
departments. “Things come in organically by virtue of 
the fact that our faculty are world leaders in their fields,” 
Schwartz said, adding that course directors meet 
monthly, and faculty have an annual retreat for discus-
sions of curriculum.
Then there is also structured process, as occurred 
with the opioid epidemic. In response to a growing 
national crisis, a task force was convened to examine 
what was being done to prepare future doctors. This 
review included assessing the curriculum, how well 
the related material was being taught and learned, and 
whether the curriculum had omitted any critically 
important information.
The curriculum integrates basic and clinical sci-
ence across the four-year continuum. Students begin 
clinical training early in medical school and revisit 
the basic sciences during clerkships, which requires 
faculty coordination to avoid unintended repetition 
and to place new material in a useful context. “We 
have structures in place to continuously examine this,” 
Belitsky said, “and it’s a constant balancing act.”
So far there has been no schoolwide effort to intro-
duce the microbiome into the formal curriculum, but 
it is happening in some courses. Cyrus Kapadia, MD, 
FW ’78, professor emeritus of internal medicine, is 
planning to introduce it in a first-year master course 
on energy and metabolism. First, he wants to find out 
what students are already learning about the micro-
biome. Then, he’ll tap into faculty experts. “We have 
some people at Yale who are known nationally for their 
work on the microbiome,” he said. “Not to use those 
people is a crime.” Kapadia hopes to have a plan for the 
course by December.
Kapadia pointed out that while there is enormous 
interest in the microbiome today, interest in gut flora 
among scientists began decades ago. One fascinating 
study published in 1934 examined the bacterial popu-
lation at different levels of the intestines of dogs and 
monkeys. This work was done decades before Watson 
and Crick’s paper in Nature on the structure of DNA, 
  Michael Schwartz
 “Things come in organically by virtue  
   of the fact that our faculty  
  are world leaders in their fields. 
In a first-year course called “Attacks and Defenses,” 
discussions of the microbiome make up part of the 
17 immunology lectures.
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and with access to only primitive microbiological tech-
niques. It wasn’t until the 1960s that more advanced 
microbiological methods enabled a quantitative assess-
ment of the microbial flora at different sites in the intes-
tines from duodenum to colon. Studies in the native 
population and in Peace Corps volunteers in the 1960s at 
such centers as the Christian Medical College in Vellore, 
India, further established the link between gut flora and 
small intestinal mucosal architecture. 
The availability of DNA sequencing methods has 
brought the field to a higher level. “The big thing now,” 
Kapadia said, “is that we are talking about the role of 
the microbiome in diseases affecting the mind, its role 
in diabetes and obesity, and its connections to cardio-
vascular disease and to cancer.” Just as the medical 
curriculum is constantly changing, the hope among 
faculty is that students will appreciate that medicine 
requires lifelong learning. Kapadia reminds his pre-
clinical students: “Your education won’t stop when you 
get to the wards!” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
The Yale School of Medicine cur-
riculum is the product of an ever-
evolving set of variables and inputs. 
Keeping it relevant requires con-
stant input and balanced perspec-
tives. From left, Richard Belitsky; 
Leigh Cromey, student services 
officer and manager of integrated 
curriculum; Michael DiGiovanna, 
co-director of integrated course 
curriculum; and Michael Schwartz 
review the curriculum changes.
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In multiple sclerosis (MS), the immune system attacks 
the nervous system, causing nerve and brain damage. Yet 
the problem might actually originate in another place en-
tirely: the gut. Yale researchers are among those teasing 
apart how MS and other autoimmune diseases may arise 
as a result of complex interactions among genes; the 
intestines’ ability to maintain a tight boundary between 
its contents and the rest of the body; and the bacteria 
that live there. 
To begin with, genetic mutations in MS “lead to 
changes in the interactions between the immune sys-
tem and the microbiome in the gut,” says David A. Haf-
ler, MD, the William S. and Lois Stiles Edgerly Professor 
of Neurology and professor of immunobiology.
A renowned researcher responsible for a number of 
seminal discoveries in MS, Hafler was first to describe 
the immune cells that attack myelin in the nervous sys-
tem. He has also identified MS-specific genetic variants—
most of them related to immune genes—and unraveled 
signaling pathways that make potential targets for drug 
treatment. In 2013, he and his colleagues published the 
landmark discovery that sodium chloride can lead to 
autoimmunity in MS. He is preparing papers for Science 
and Cell that map out the disease’s genetic architecture, 
a culmination of almost two decades’ work. 
Hafler is among a group of scientists who are un-
covering genetic clues linking MS to the gut. In 2011, he 
co-authored a paper listing scores of culprit MS genes, 
one called INAVA, whose products show up in the gut. 
Researchers recently found that INAVA also plays a key 
role in Crohn’s disease—a type of inflammatory bowel 
disease (IBD) that often accompanies MS. In a March 
2018 paper in Science, a team at the Broad Institute 
of MIT and Harvard reported that the INAVA variant 
seems to loosen the integrity of the intestinal barrier, 
rendering it permeable to molecules that shouldn’t be 
able to pass through.
That phenomenon is sometimes called “leaky gut.” 
Findings like the Broad team’s hint at the importance 
of the gut lining to autoimmune disease. The digestive 
tract is lined by epithelial cells that are tightly connect-
ed to one another, forming a barrier between the food 
being digested and the bloodstream. Abnormal perme-
ability of that layer has been observed in people with 
IBD, as well as in mice suffering from a version of MS. 
Good bugs 
gone bad
Helpful in some places, bacteria 
can cause conditions like MS 
when they break through the 
body’s barricades.
by jenny blair, md ’04
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Though leaky gut has become a popular scapegoat 
in complementary medicine circles for everything 
from autism to acne, it likely constitutes a real link to 
inflammation, says Noah Palm, PhD ’11, FW ’15, assis-
tant professor of immunobiology, who studies the links 
between autoimmune disease and the gut microbiome. 
His lab explores how communities of gut bacteria may 
influence not only the immune system, but also neuro-
developmental disorders like autism.
“There’s a lot of suggestive evidence in the literature 
that at least some sort of barrier disruption co-occurs 
with a lot of these [autoimmune] diseases,” Palm says. 
Leaky gut seems to arise in a number of ways. In 
some cases, bacteria may drill down to the barrier and 
loosen it directly, Palm says. 
Chronic high blood sugar can also do it, accord-
ing to a team led by former Yale postdoctoral associ-
ate Eran Elinav, MD, PhD, now at Israel’s Weizmann 
Institute of Science. Elinav’s group linked leaky gut to 
obesity and to type 1 diabetes, an autoimmune disease, 
in a March 2018 paper in Science. 
When the gut’s barrier comes down, it can let in bad 
actors. In genetically susceptible mice, certain bacte-
rial species can traverse the intestinal barrier; travel 
to the liver and lymph nodes; and trigger a lupus-like 
autoimmune disease, according to a group led by Martin 
Kriegel, MD, PhD, FW ’06, adjunct assistant professor 
of immunobiology at the School of Medicine. The team 
members, who found the same bacteria in liver biopsies 
of human patients with lupus, also published their results 
in a March 2018 issue of Science. 
There’s strong evidence to suggest that bacteria 
are central to what goes wrong in MS and other auto-
immune diseases. 
“One of the things that we’re doing very intensively is 
looking at the microbiome in MS,” Hafler says. “We and 
others have found that there are clearly abnormalities.”
For instance, MS patients have a lower-than-
normal abundance of Lactobacillus species—the kind 
found in yogurt—and a higher abundance of Rumino-
coccus, a group of bacteria that can break down resis-
tant starches. Exactly how such differences translate 
into disease is still unclear. But in mouse models of MS, 
inflammatory cells involved with the disease have been 
observed to be influenced by gut bacteria. 
Moreover, a microbiome “transplant” from MS 
patients into mice can actually provoke MS-like symp-
toms, according to two papers appearing last fall in 
Proceedings of the National Academy of Sciences.  
The patients’ bacteria seem to alter immune T cells’ 
behavior in the mice, leading to a type of encephalitis 
similar to MS. 
Bacteria also seem to influence brain cells. Tryp-
tophan is an essential amino acid found in protein-rich 
foods like meat, oats, and peanuts. It is converted in 
the body into the neurotransmitter serotonin and the 
sleep-related hormone melatonin. But in a March 2018 
paper in Nature, a multinational group of researchers 
reported that molecules from bacteria that metabo-
lize tryptophan were also controlling microglia cells in 
the brain that can stimulate astrocytes to produce an 
MS-like disease in mice. Such bacterial influence, the 
authors suggested, may help explain why problems 
with the gut microbiome can impair recovery from 
spinal cord injury—and why certain other species seem 
to help recovery instead. 
“The most important questions are: What is the 
microbiome? And what metabolites is it making in 
relation to the genetic architecture of the individual?” 
Hafler says. “That’s what I think it comes down to.”
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Evolving 
attitudes
How microbes are changing 
received wisdom.
As researchers compile evidence 
of microbiome-related afflic-
tions, faculty like Noah Palm help 
place discoveries in their proper 
contexts. In many cases, in which 




“There are a lot of microbiome evangelists out there 
who would tell you this has changed our world; it’s 
changed it already and will continue to change it,” 
says Noah Palm, PhD ’11, FW ’15, assistant professor 
of immunobiology. Palm heads the lab that seeks to 
understand the mechanisms by which the microbiome 
interacts with the human hosts’ immune system, with 
the ultimate goal of using these interactions to combat 
disease. However, “so much is still in question, at a basic 
science level, that must be understood before research 
addresses how the microbiome can be used in therapies.” 
The impatience and an eagerness to take advantage 
of the resources brought by hype surrounding the 
microbiome, says Palm, means that there is pressure to 
fulfill the great promise of the microbiome too hastily. 
“You have one or two failures and everyone gives up on 
the whole thing. That’s actually one of my major fears 
in terms of the whole field of biotech. I do believe there 
will be transformative, paradigm-shifting therapies 
that target the microbiome. But it’s not going to  
be next year.” 
Rather than evangelism, Palm says a common view 
at Yale is a more “conservative, data-driven kind of 
perspective,” he says. More conservative scientists 
say microbiome research must focus on establishing 
cause-and-effect evidence that the microbiome impacts 
disease on a molecular level, rather than just inferring 
causality through observation. According to Eduardo 
Groisman, PhD, the Waldemar Von Zedtwitz Professor 
of Microbial Pathogenesis, it is very difficult to locate a 
sure causal relationship between a microbe in the gut 
microbiota and a function in its host, but there are many 
undeniable correlations. “The underlying assumption of 
all these correlations, which is very intuitive, is that if 
you have an abundance of a particular type of bacteria 
from the microbiome, then that organism is responsible 
for a particular behavior,” he says. Groisman studies 
bacteria, such as the gut-symbiotic Bacteroides thetaio-
taomicron, in an attempt to find the mechanism behind 
how organisms know when and how to shut particular 
genes on and off.
“To a lot of scientists in mature fields, it’s not cau-
sation until you have a level of molecular insight that 
makes you comfortable with how it’s really working, 
not just that it works,” says Palm. To them, causation 
means more than a presence or absence of particular 
microbes or groups of microbes in the gut that cause 
disease, proof of their function, and how they exert 
that function. The challenge of causation is further 
confounded by the vast diversity in the microbiome, 
which varies widely among both individuals and 
populations. “If you compare it to understanding, say, 
the function of human genes, it’s of an intractable 
magnitude. There are 150 times more genes in your 
microbiome than in your own genome,” says Palm. The 
microbiome is also intensely sensitive and can change 
within an individual even within a day.
Further, the expense of experimentation influences 
the research. Because of this, “there is a temptation 
to generate a lot of data,” says Groisman. “What these 
correlations are providing is information. But one can-
not equate information with knowledge.”
Just as the ancient Greeks centered their understanding of 
the human body on its four humors, and later eras separately 
proclaimed the heart, the brain, and even the genome as the 
leading player, the microbiome is now taking center stage. This 
superorganism, as it has come to be known, has become a 
major force in the biomedical research marketplace, attracting 
substantial financial investment and taking up more and more 
column inches in publication space. It is also becoming equally 
clear that this young field still has a long way to go before it truly 
shifts the paradigm for understanding disease.
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In the past 10 years, major strides have occurred in 
moving from correlation to causation in microbiome 
research, with investigators using animal models, 
particularly gnotobiotic, or germ-free mice, for proof. 
Palm’s postdoctoral work with Sterling Professor of 
Immunobiology Richard Flavell, PhD, used immuno-
globulin A to identify the bacteria in the microbiome 
that affect irritable bowel disease (IBD). Using these 
mice, who are born completely sterile, the team was 
able to isolate and identify a particular microbe that 
drives the disease. “To me that’s causation,” Palm says. 
“This bug is causing this disease.”
Groisman points to the most established use of the 
microbiome in therapy as an example: fecal material 
transfer, an FDA-approved treatment for the stubborn 
and potentially deadly Clostridium difficile infec-
tion, or C. diff. The science behind this therapy, which 
has been shown to work in the vast majority of C. diff 
cases and even save lives, is based on an observed cor-
relation, not causal effect, says Groisman. It is a very 
recent development, with the long-term effects still 
unstudied. “How many of these correlations will hold 
over time? We will see.” 
When it comes to the microbiome, “there are still 
massive gaps in our fundamental knowledge,” says 
Palm. Despite these growing pains, the field is making 
progress toward maturity, balancing the excitement 
over the potential of the microbiome with rigorous 
study. “I think we have at least the beginnings of this 
tool set to do the correlation-to-causation transition,” 
says Palm. The tool set includes increasing improved 
DNA sequencing, as well as culturing techniques that 
allow annotation of the vast number of microbes that 
make up the microbiome. “The hope is that by leverag-
ing cutting-edge tools and feeding the data we get into 
computational pipelines, you start to take bigger bites 
of the apple, even though the problem seems intrac-
table at this time,” says Palm. With careful use of the 
resources available, the hope is that all this informa-
tion will eventually turn to true knowledge. 
This young field is not just a flash in the pan. “The 
microbiome is not going away,” says Palm. “Just like 
neurobiology is not going away. Nobody is going to stop 
studying the brain. Same thing with the microbiome.”  
/yale medicine magazine
Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine 
Magazine.
Working alongside 
researchers like Richard 
Flavell, Palm looks for 
causal relationships 
between bacteria and 
health outcomes. Scien-
tists have established 
promising correlations, 
but the mechanisms by 
which bacteria contrib-
ute to a healthy immune 
system remain elusive.
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“Consider the gut microbiome as the center of the 
world,” says Li Wen, MD, PhD, FW ’97, associate pro-
fessor of medicine (endocrinology). At the center of 
a lined notepad, Wen draws a circle: this is the gut 
microbiome. Radiating out, she draws arrows that 
point to a wide span of human diseases, including 
cancer, problems with the body’s circadian rhythm, 
and autism. Among them are diabetes and obesity. 
Yale researchers, including Wen, have been at the 
center of pivotal studies that elucidate the gut mi-
crobiome’s connection to these disorders. 
In a trial published in Nature way back in 2008, Wen 
drew a line connecting the gut microbiome and type 1, 
or juvenile, diabetes. Unlike type 2 diabetes, which is 
largely driven by such environmental factors as diet, 
type 1 is an autoimmune disease in which the body’s 
innate immune system does not properly function and 
attacks its own insulin-producing beta cells. Using 
genetically modified diabetic mice, Wen and a team 
pinpointed a protein molecule, MyD88, that acted as a 
“master controller” of innate immunity. The mice bred 
without the MyD88 molecule in a pathogen-free envi-
ronment did not develop type 1 diabetes. “We thought, 
‘Wow, we’ve got a molecule with the potential to trans-
late into clinical use in humans,’” recalls Wen. 
As is often the case in research, Wen encountered 
a complication: the mice, while diabetes-free, devel-
oped opportunistic bacterial infections. “We know 
that when there is an infection, it affects the immune 
system, so we needed to eliminate this possibility,” she 
says. To do so, they performed the experiment with 
germ-free mice, which are bred to have no microorgan-
isms of any kind living in or on them. Stunningly, the 
diabetes returned.
“Science is like a dog chasing its own tail,” Wen 
says. To understand this development, the team con-
taminated those germ-free mice with gut bacteria. The 
diabetes rates in these mice dropped drastically. The 
team concluded that a combination of genetics and 
the commensal bacteria in the gut of the mice together 
halted the development of type 1 diabetes, and this 
combination would be critical in understanding how 
autoimmune diseases develop. 
“Genes alone do not explain these diseases.  
Genetic shifts cannot occur as rapidly as immune  
An end to 
dieting




diseases have been rising,” says Martin Kriegel, MD, 
PhD, FW ’06, adjunct assistant professor of immunobi-
ology and of medicine (rheumatology). 
Kriegel, in a study published earlier this year in 
Science, discovered that gut bacteria in mice can break 
through the gut lining; travel to other organs; and 
trigger an immune response, with implications for the 
treatment of lupus, another autoimmune disorder. 
“Environmental factors also have to go through the so-
called barrier organs—the skin, the lungs, the gut—that 
are covered with microbes. The combination of genes, 
environmental factors, and their influence on resident 
microbes contributes to disease onset.” 
Yale researchers have established a causal link be-
tween the microbiome and obesity, which is a driver of 
type 2 diabetes. Rachel Perry, PhD ’13, FW ’17, assistant 
professor of medicine (endocrinology), discovered 
through a series of experiments that the mice with 
high-fat diets produced high levels of acetate, a short-
chain fatty acid, which increases insulin secretion and 
raises the drive to eat. This acetate, says Perry, is de-
rived from the microbiome itself. The study, which she 
conducted with Gerald Shulman, MD, PhD, the George 
R. Cowgill Professor of Medicine (Endocrinology) and 
co-director of the Yale Diabetes Research Center, was 
published in Nature in 2016. 
Much like Wen’s discovery, “we got into this 
largely by accident, as happens with a lot of interesting 
science,” says Perry. When conducting experiments 
that used acetate as a tracer, she and a team in Shul-
man’s lab noticed that obese animals were producing 
higher levels of acetate. But they did not know where 
in the body it was being produced, or why. 
“Surprisingly to us, these obese mice had a large 
increase in their plasma insulin concentration,” Perry 
says. “Obese patients who are not yet diabetic have 
very high plasma insulin concentrations, and that is 
what is required to keep their blood sugars in the nor-
mal range. When we saw this increase in acetate, we 
thought maybe these two things are related.”
The team discovered that acetate drives this 
increased insulin secretion through activation of the 
parasympathetic nervous system, leading the re-
searchers to the gut microbiome as the source of that 
acetate. Shulman and Perry are now looking to identify 
the specific microbe or set of microbes in the microbi-
ome that set off this reaction. 
The ultimate goal of finding these types of links, 
says Wen, is to develop the ability to test for particular 
microbes and use them as biomarkers, essential for 
early prevention. The next step is to make the leap from 
animal to human studies, which is fraught with chal-
lenges. “I like to compare it to the human genome field 
two decades ago, which was very exciting but also very 
descriptive,” says Kriegel. “Now the field has matured. 
A lot of insight is gained from animal studies, but these 
studies are not always translatable to humans.”
The ever-shifting constitution of the microbiome 
is just one complication that frustrates inquiry. In their 
work, “we were struck by how quickly the microbiome 
changes,” says Perry. “In rats, when we took food away 
for just 48 hours, there were drastic shifts in their 
acetate production, and, I suspect, in their microbial 
composition. It took only two days of not having any-
thing to eat for that to change very drastically. And the 
challenge in humans will be, how do we know we are 
sampling what we think we are sampling?” This is the 
nature of transformative science. 
“The more one studies,” concurs Wen, “the more 
questions one has.”
Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine 
Magazine.
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Because Joseph Marshall 
Flint, MD, was trained 
as a research anatomist, 
many at Yale did not see 
him as their top choice for 
professor of surgery at the 
School of Medicine. When 
the administration offered 
Flint the position, other 
faculty and physicians 
 Joseph Marshall Flint’s  
genius for wartime surgery
Jacqueline Rocheleau
  A heroic contribution  
 to medicine
complained: the doc-
tor’s only former surgical 
experience was during a 
sabbatical year in Germany 
and Austria in 1906, right 
before he arrived at Yale. 
Despite the controversy, 
Flint would prove his value 
to Yale during his 14-year 
career there, leading its 
mobile hospital unit in 
World War I and reforming 
surgical education.
Before he accepted the 
position as professor of 
surgery, Flint had condi-
tions. He wanted labora-
tories, classrooms, and 
offices “in close contigu-
ity with the hospital and 
dispensary,” wrote Flint’s 
Yale colleague, Samuel 
Clark Harvey, PhB 1907, 
MD 1911. In the early 20th 
century, medical schools 
did not usually have full-
time faculty or resources 
dedicated to research and 
student training. 
Around this time, 
however, a movement to 
institute these changes in 
medical schools was begin-
ning. Flint joined the move-
ment and helped restore 
Yale’s waning reputation as 
a top medical school. For 
example, to make up for 
the fact that medical stu-
dents could not work with 
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patients, Flint instituted a 
dog surgery course mod-
eled after the one Harvey 
Cushing, MD, had pio-
neered at Johns Hopkins. 
European conflicts 
interrupted Flint’s prac-
tice as a professor. During 
the Greco-Bulgarian War 
in 1913, a precursor to 
World War I, Flint served 
as a surgeon in an Athens 
hospital. Once World 
War I began, Flint started 
volunteering on behalf 
of the French before the 
United States joined. He 
worked as a surgeon in a 
French military hospital 
in 1915 and wrote papers 
on military medicine. He 
also developed an X-ray 
photography method to 
locate foreign bodies and 
refined suspension meth-
ods used to treat fractures. 
Flint took particular 
interest in French military 
hospital design. After five 
months volunteering there, 
Flint told the Yale Daily 
News, “Not the least inter-
esting feature of military 
surgery is the organization 
of a military hospital.”
In fact, according to an 
article in the Yale Daily 
News, Flint had pushed for 
Yale to join the war and 
provide a Yale Hospital for 
wounded European sol-
diers as early as 1914. 
In 1917, a few weeks 
after the U.S. declared 
war on imperial Germany, 
OPPOSITE PAGE Flint’s “Mo-
bile Hospital No. 39” was 
based on experiences with 
systems he had observed in 
the French military, and dur-
ing volunteer work with the 
Greek alliance during the 
Second Balkan War of 1913.
LEFT Period publications 
were positively effusive in 
their praise for Flint’s hospi-
tal, which incorporated  
the very latest in organiza-
tional theory.
BELOW A depiction of Flint’s 
Mobile Hospital from a 
scrapbook in the George 
Milton Smith collection, 
made by his brother, J. Andre 
Smith, who served in WWI.
LEFT Overhead view of a 
3-D architect’s model built 
for presentation purposes. 
The library still owns a copy 
of the model, though it is 
maintained only as a histori-
cal curiosity.
Flint was asked to head 
the efforts to design and 
implement a mobile hos-
pital for American soldiers 
in France. Flint’s work 
with the French resumed 
as he studied their mobile 
hospitals to perfect the 
American counterpart. 
From 1917 to 1919, 
Flint served as the com-
manding officer of Mobile 
Hospital Unit No. 39, the 
Yale Unit, of the American 
Expeditionary Forces. He 
designed the Yale Unit for 
maximum efficiency, mod-
eling it after both French 
hospitals and Ford’s fac-
tory assembly lines. If 
soldiers were the product 
along the assembly line, 
the staff members were the 
factory workers, staying 
in place to perform their 
assigned duty as the belt 
rolled along to maximize 
hospital efficiency. 
According to Melissa 
Grafe, PhD, the John R. 
Bumstead Librarian for 
Medical History and head 
of the Medical Historical 
Library, Flint’s design was 
efficient not only on paper 
but also in practice, low-
ering the average operat-
ing time per patient.
Because of the hos-
pital’s success, Flint was 
awarded the Distinguished 
Service Medal with a 
citation that, according 
to Harvey, read: “When 
placed in a position of great 
responsibility as com-
manding officer of Mobile 
Hospital No. 39 at Aulnois-
sous-Vertuzey, France, he 
used extraordinary skill 
and sound judgment in the 
organization and opera-
tion of that unit, the first 
of its kind in the American 
Expeditionary Forces.” 
During his service as 
commanding officer, Flint 
contracted the Spanish 
Flu and never fully recov-
ered. Throughout the rest 
of his life he experienced 
persistent pulmonary 
problems. In Yale’s col-
lection of his writings, 
several books are filled 
with hand-drawn medi-
cal charts, colored pencils 
and red ink tracing the 
trajectory of his health. 
Flint died in 1944, living 
long enough to see Mobile 
Hospital Unit No. 39 rein-






























 Akiko Iwasaki  
  and the  
Mighty Microbiome
»
iga ueno castle, also known as hakuho or  
White Phoenix Castle, is considered one of the more 
beautiful examples of an architectural style popular in 
Japan during its early modern period. Located in Mie 
Prefecture, Iga Ueno Castle was built to project political 
legitimacy during great civil unrest. The castle provides 
a visually striking reminder of a time in human history 
when stability was just a couple of bad harvests from 
breaking down, and a healthy country required tall, 
thick stone walls to have a chance of surviving. Without 
those great defensive bulwarks, feudal Japan’s fledgling 
government might not have lasted to evolve into the 
form that it holds today.
example involved medical trials 
with mice raised in laboratories.
“We found a few years ago that 
when you treat mice with anti-
biotics, and you get rid of most 
of the microbiome, these mice 
become susceptible to influenza,” 
says Iwasaki. She explained 
that the microbiome and the 
mouse’s “natural” immune sys-
tem work together to keep each 
other healthy and prepared for 
infection, and that when one is 
compromised the entire system 
falls apart. “It seems that the 
microbiome is important for the 
well-being of the immune system 
in general,” Iwasaki says.
Scientists have known for 
some time that animals with 
germ-free guts are at higher risk 
of disease and defect. Iwasaki 
notes that these early observa-
tions from decades ago relied 
on culturing bacteria from stool 
samples with crude equip-
ment, but that the techno-
logical advances of the last three 
decades have spurred a kind of 
categorical revolution in the field. 
“With sequencing technology, 
we can actually tell what type of 
bacteria live in a particular gut, 
even the ones one can’t culture 
in a lab. We have the whole pic-
ture of what kinds of bacterial 
species are present in a healthy 
or unhealthy animal or, increas-
ingly, person,” says Iwasaki.
One portion of this equa-
tion that isn’t understood yet is 
the mechanical relationships 
between body and microbe; which 
causes produce which effects. In 
part this difficulty is due to the 
Perhaps it is fitting, then, that 
a child of Iga should be among 
the world’s foremost experts 
on biological defense—specifi-
cally, conceptualizing how the 
human body defends itself from 
illness. Yale’s Akiko Iwasaki, 
PhD, the Waldemar Von Zedtwitz 
Professor of Immunobiology 
and of molecular, cellular, and 
developmental biology, and a 
Howard Hughes Medical Institute 
investigator, has dedicated her 
professional career to research-
ing how the body perceives and 
responds to certain infections.
As someone who helped 
develop the field of antivi-
ral immunology, Iwasaki 
often focused her inquiries on 
the microbiome. One recent 
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Akiko Iwasaki, center, is 
excited about the many 
recent technological 
and scientific advances 
that have helped break 
open the floodgates 
for insights into 
infection. Women’s 
Health Research at Yale 
undergraduate fellows 
Haleigh Larson, left, and 
Rose Davis look on.
create conditions for discomfort 
or even death. Many recent 
scientific advances have been 
accompanied by an exponen-
tial expansion in the number 
and complexity of questions  
for laboratories. 
After the period of civil 
unrest ended in Japan, White 
Phoenix Castle deteriorated and 
was allowed to fall into ruin. 
Later, though, it was rebuilt for 
its architectural beauty and his-
torical significance. One might 
debate its utility as a defensive 
sophistication of the microbiome. 
Another difficulty, according to 
Iwasaki, arises because the micro-
biome itself is far more compli-
cated than is easily imaginable.
“Going past the microbiome, 
and the human genome, you 
have the metagenome, which 
includes all the phages or 
viruses that live within the 
bacteria, and other viruses that 
live inside our cells. So, we must 
consider the virome, too.”
Another recent discovery is 
that the 90 percent of human 
DNA previously considered “use-
less junk” seems to have purpose, 
and may not be human DNA at 
all. “Retroelements occupy almost 
half of our genome,” says Iwasaki, 
noting that this is “huge real 
estate compared to our coding 
sequence. And we have very little 
idea what they’re doing, though 
they seem much more vital than 
originally envisioned.”
Iwasaki finds the question 
of infection fascinating—why 
under some circumstances 
bacteria and viruses are able 
to coexist with the body in 
healthy numbers and may even 
be critical to its healthy func-
tion; while under different cir-



















the first Native Ameri-
can woman to graduate 
from Yale School of 
Medicine, spoke with 
Peter Salovey as part of 
the President’s Women 
of Yale Series. She 
discussed issues like 
identity, displacement, 
addiction, and the 
power of perseverance.
For more on their talk,  
visit ymm.yale.edu/talk
structure necessary to the sur-
vival of Japan’s government, but 
it and castles like it are signifi-
cant in ways their builders may 
not have imagined. As it turns 
out, the health or illness of a 
system can be immensely com-
plicated, not just on a micro-
scopic level but on a national 
level as well. 
—Adrian Bonenberger
»
From the killing  
fields to the halls  
of power
When Yale Medicine Magazine 
last checked in with SreyRam 
Kuy, MD, MHS ’09, FW ’09, it was 
in the aftermath of Hurricane 
Harvey last summer. Kuy, associ-
ate chief of staff at the Michael E. 
DeBakey Veterans Affairs Medical 
Center in Houston, was run-
ning the hospital’s emergency 
response. She spent days on end 
making sure the hospital took 
care of its patients and staff, even 
taking a turn working the cafete-
ria’s chow line. 
Kuy has served the VA for 
nearly two decades, in roles 
spanning from Deputy Under 
Secretary for Health, overseeing 
a $14.5 billion-dollar budget, to 
operating on colon cancers and 
gangrenous limbs as a general 
surgeon. “In any capacity, it is 
an honor to serve these heroes,” 
Kuy said.
She’s also been named one 
of 10 recipients of the Women of 
Worth award by L’Oréal Paris and 
is a Daily Point of Light—the latest 
in a roster of awards that includes 
the Ford Family Foundation’s 
Gerald E. Bruce Community 
Service Award and the American 
College of Surgeons’ the Dr. Mary 
Edwards Walker Inspiring 
Women in Surgery Award. A 
common thread is her service 
to such vulnerable and under-
served populations as veterans 
and mothers on Medicaid. Given 
her life story, said Kuy, “paying it 
forward” is nonnegotiable.
“I am a child survivor of 
genocide,” she said. “To be able 
to live in America is a privilege I 
am very grateful for. I owe it to 
the generosity of strangers who 
saw value in helping me when 
I had nothing of value to give 
back and there was no reason to 
believe in me.”
Kuy was born in Cambodia in 
1978. This was three years after 
the Khmer Rouge took power 
and emptied the capital, Phnom 
Penh, at gunpoint. Kuy’s father 
had a government job and her 
mother was a school teacher. The 
Khmer Rouge executed everyone 
with an education, Kuy’s parents 
feigned illiteracy. With her older 
sister, they marched hundreds 
of miles to forced labor camps in 
the jungle. Kuy was born in one of 
those camps.
The family saw a chance to 
escape in 1979, when Vietnam 
invaded Cambodia. They walked 
by night and hid during the day 
until they reached a refugee 
camp in Thailand. Safety still 
eluded them, however. A rocket-
propelled grenade landed on 
their tent, injuring Kuy and her 
mother. A Red Cross surgeon 
saved their lives.
Three refugee camps later, the 
family landed in the Philippines, 
where a Christian missionary 
helped them enter the United 
States as refugees. They settled 
in Corvallis, Ore., in 1981. Kuy’s 
father worked as a janitor at 
Oregon State University and her 
mother was a housekeeper at 
Good Samaritan Hospital.
“My mom used to mop the 
floors of the operating room 
and now I work as a surgeon; 
my dad mopped the floors at 
Oregon State University, and 
that’s where I graduated,” Kuy 
said. “That is how amazing 
America is.”
After college and medical 
school in Oregon, Kuy com-
pleted her surgery residency at 
the University of Texas Health 
Science Center at San Antonio 
and then applied to the Robert 
Wood Johnson Clinical Scholars 
Program that brought her to Yale.
“My journey as a health care 
public servant has been as a direct 
result of the skills I gained at Yale,” 
she said. Biostatistics, public 
health, computer programming, 
and working with large data sets 
were important, she said, but she 
also learned “the courage to take 
on challenges.”
In 2017, as chief medical offi-
cer for Medicaid in the state of 
Louisiana, Kuy’s challenge was 
the opioid crisis. That year she 
was selected to the Presidential 
Leadership Scholars Program, a 
partnership among the presiden-
tial centers of Lyndon B. Johnson, 
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Kuy’s accolades extend beyond 
medicine and health policy. She is 
an accomplished writer with arti-
cles published in the Los Angeles 
Times and the Washington Post. 
Her novel, The Heart of a Tiger, is 
based on her family’s experiences 
in the killing fields.
“My life is a miracle,” she said. 
“It is a testament to the grace 
of God and the extraordinary 
human capacity for compassion.”
—John Curtis
George H.W. Bush, Bill Clinton, 
and George W. Bush that brings 
together mid-career leaders from 
diverse backgrounds.
The fellows met once a month 
for four-day workshops led by 
former presidents, cabinet sec-
retaries, and other policy lumi-
naries. Kuy sought ideas on the 
opioid crisis from her mentors 
and colleagues, and came away 
from each meeting with ideas that 
she brought back to Louisiana. 
“I walk into the classroom and 
there’s a judge, a lawyer, a teacher, 
a poet, a Marine, a nurse—each 
offering a perspective on how to 
mobilize stakeholders,” she said. 
“I would come back from the class 
just energized.”
Kuy organized town halls; 
held symposiums; and ran 
seminars for doctors, patients, 
and stakeholders. Her solu-
tions included payment reform 
to reduce overprescription of 
opioids and increasing acces-
sibility to naloxone, used to treat 
overdoses. “We reduced opioid 
prescriptions among new users 
by 40 percent,” Kuy said.
A child survivor of geno-
cide, SreyRam Kuy has 
followed an extraordi-
nary path into medicine. 
In Houston, she helped 
organize responses to 
















   The immune system  
 & acts of kindness
Has public awareness 
about the immune sys-
tem and immunology 
changed during your 
career? Yes. The central 
driving trend for growing 
awareness has been a rec-
ognition that the immune 
system is involved—often 
quite directly—in almost 
every human disease. 
That’s particularly true 
for what we call the “dis-
eases of modern society,” 
like obesity, diabetes, and 
heart disease. There’s also 
growing recognition of 
the process of inflamma-
tion and the role it plays 
in initiating or exacer-
bating diseases. Another 
major trend in awareness 
is within cancer immu-
nology. Immunotherapy 
has revolutionized our 
thinking about cancer 
and how it can be treated. 
How would you sum-
marize your research 
focus now? I’ve gotten 
very interested in the 
question of how recombi-
nation processes evolved. 
They are so unusual that 
it immediately raises the 
questions: Where did they 
come from? How did the 
human body come to have 
these processes? We think 
we can trace the V(D)J 
recombination process to 
a piece of DNA known as 
a transposon. This is an 
autonomous, mobile piece 
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DAVID G. SCHATZ, PHD, chair of Yale School of Medicine’s 
immunobiology department, can explain mind-bendingly 
complex processes of the human body’s immune system in 
relatable terms. For instance, here is his description of a pro-
cess that produces antibodies to fight viruses and bacteria as 
follows: “This immune system reaction treats the chromo-
some like a big long string. It comes in with molecular scis-
sors, cuts the string, and then different enzymes come in 
and tie the string back together in a new configuration.”
{ To nominate a subject for Q&A, contactYale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu
What Schatz just described is 
called the variable, diversity, 
and joining, or V(D)J recom-
bination process, and it allows 
T cells and B cells to randomly 
assemble different gene seg-
ments. As a graduate student 
at MIT in the lab of David 
Baltimore, a virologist who 
shared the 1975 Nobel Prize in 
Physiology or Medicine, Schatz 
established an assay to detect 
V(D)J recombination activ-
ity. Then, in collaboration with 
another doctoral student, he 
used this assay to isolate and 
discover two key enzymes in 
this process called RAG1 and 
RAG2. That groundbreaking 
contribution to the field hap-
pened almost 30 years ago. 
Schatz never slowed his pace. 
Earlier this year, Schatz, 
the Waldemar Von Zedtwitz 
Professor of Immunobiology and 
professor of molecular biophysics 
and biochemistry, was elected to 
the National Academy of Sciences 
in recognition of his biochemi-
cal insights into RAG function 
and evolutionary origins. He was 
also a Howard Hughes Medical 
Institute investigator between 
1991 and 2017; has been elected to 
the American Academy of Arts 
and Sciences; and is a fellow of 
the American Association for the 
Advancement of Science. 
Yale Medicine Magazine 
caught up with Schatz, who 
earned his BS and MS degrees in 
molecular biophysics and bio-
chemistry from Yale University 
in 1980, to learn more about 
the intricate processes of the 
immune system and what he 
values most in colleagues. 





of DNA that encodes an 
enzyme that’s able to bind 
to an element, snip it out 
of one location, float, and 
place it into another one. 
We believe that’s how the 
immune system can make 
hundreds of millions of 
different antibodies. Our 
antibody genes are broken 
up into discontinuous bits 
and fragments of DNA, 
and the enzyme comes 
along and allows those 
fragments to join in new 
configurations. So, we 
owe our adaptive immune 
system to this mobile DNA 
element that gave us the 
capacity to snip and cut 
and rearrange our DNA. 
What comes to mind 
when you think about 
the microbiome and 
immunology? The 
microbiome has come 
onto the stage with 
incredible speed. Much 
like the immune system 
itself, which influences 
almost every process 
in the body, the micro-
biome—we are learn-
ing—affects so many 
different processes. There 
is incredibly sophisti-
cated intercommunica-
tion going on between 
the immune system and 
the microbiome. In our 
own department, Noah 
Palm, PhD, assistant 
The brilliant ideas that 
drive science forward can 
happen at any time from 
any one, so you just need 
to make people as free 
as possible from stresses 
and pressures. The other 
point I would like to 
convey is the excitement 
that comes from learning 
something or discovering 
something no one else 
has ever known before. 
I would love to pass on 
that deep love of making 
new discoveries.
professor, is studying how 
the microbiome affects 
health and disease states 
in an area that few people 
think about, which is the 
metabolites that bacteria 
produce. These are small 
organic molecules that 
bacteria either have on 
their surface or secrete. 
We know virtually noth-
ing about what these tens 
of thousands of chemicals 
tell our body, what they 
signal our body to do 
or to think. Noah is just 
beginning to explore the 
diversity of those chemi-
cals and their effects. 
What message do you 
have for today’s future 
scientists? Once, during 
a conversation with David 
Baltimore, I asked him 
what made a great leader. 
His answer was one word. 
“Generosity.” That suc-
cinctly captures much 
of what I admire in the 
great leaders I’ve known. 
I would like to convey 
the message that respect 
and a humble eagerness 
to learn from one another 
are incredibly important 
parts of doing science and 
being a scientist. Acts of 
kindness, sharing, coop-
eration, collegiality—all 
of these have an enor-
mous impact on atmo-
sphere, and ultimately, 
the productivity of the 



















  Improving college  
 students’ mental health
   By Cathy Shufro
It’s a rare parent who doesn’t 
feel a twinge of anxiety 
when dropping off a child 
at college. Although par-
ents may worry most about 
drinking and sexual assault, 
more subtle disturbances can 
also hinder college students, 
according to campus psychi-
atrist Marcia Morris, MD ’89. 
Recently, Morris has been 
seeing more students who 
feel extremely lonely or are 
obsessed with perfection.
Those are among the 
problems she addresses in 
The Campus Cure: A Parent’s 
Guide to Mental Health and 
Wellness for College Students. 
Drawing on research and 
on 25 years as a psychiatrist 
at the University of Florida, 
Morris also discusses suicidal 
behavior, financial stress, 
eating disorders, struggles 
with sexual identity, and 
psychosis. “This is my way of 
trying to help parents prevent 
some of these problems, or to 
address things quickly,” says 
Morris, the associate program 
director for psychiatry at the 
University of Florida’s Student 
Health Care Center. Morris 
is also an associate professor 
at the university’s College of 
Medicine and the mother of 
two recent college graduates. 
In The Campus Cure, 
Morris explains how to rec-
ognize trouble. For instance, 
she advises parents to look at 
their children’s grades each 
term; bad grades may signal 
problems that a student has 
managed to hide. For a fam-
ily facing a crisis, Morris 
provides step-by-step guid-
ance on how to proceed.
She confirms that 
unchecked drinking is com-
monplace in college. One 
recent study showed that a 
third of students had binged 
on alcohol during a two-week 
period. (Binging means four 
or more drinks in two hours 
for a woman and five or more 
for a man.) When parents 
warn their children against 
misusing drugs and alcohol, 
Morris advises them to focus 
on health, not morality. She 
notes that young people who 
observe that their parents 
moderate their drinking are 
likely to do the same. 
Sexual predation is also 
widespread. By graduation 
day, one in 10 female stu-
dents will have experienced 
forced penetration. Un- 
wanted sexual contact 
affects one in four students 
who are transgender, queer, 
or nonconforming, and one 
in 20 men. Morris reminds 
parents not to blame a child 
who is victimized. 
Although college social 
life may look appealing, 
Morris reports that many 
students feel lonely. One 
study found that one in 
four students had felt “very 
lonely” during the previ-
ous two weeks. Feeling 
isolated increases the like-
lihood of depression and 
suicide, whereas more robust 
social support correlates 
with higher grades. Morris 
points out that children who 
grew up on Snapchat and 
Instagram have missed some 
chances to practice face-to-
face interaction. 
She suggests that stu-
dents seek friends by joining 
clubs, cultural groups, and 
religious organizations. A 
student might arrive early 
at class and then chat with 
a classmate, join a study 
group, or arrange to meet a 
potential friend for lunch. 
Group therapy can help 
young adults with social 
anxiety disorder, and Morris 
recommends The Shyness & 
Social Anxiety Workbook. 
She has also noticed an 
increase in extreme perfec-
tionism. Some people call it 
“duck syndrome”: appearing 
to excel effortlessly while 
madly paddling just below 
the water line. “Parents 
should tell their child that 
they might get a C or even an 
F in a class, and help them 
recognize that sometimes we 
do fail at things,” says Morris. 
External factors may con-
tribute to an obsession with 
success, including the pres-
sure to find a job with a salary 
sufficient to repay loans.
Although The Campus 
Cure addresses distressing 
problems, the book pro-
vides case studies and action 
checklists that can help par-
ents and students weather 
difficulties. Morris sympa-
thizes with parents of college 
students: “I want to make 
sure that when parents read 
the book, there’s no sense 
of guilt. Raising kids is very 
challenging, and there’s not 
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book review
ON A B A L M Y M AY A F T E R NO ON, longtime Yale School of Medicine personality, beloved mentor, 
accomplished doctor, and dedicated physician Margaret “Peggy” Bia, MD, FW ’78, stepped away 
from her official responsibilities. Surrounded by former patients, colleagues, friends, and well-
wishers, like David Mulligan, MD, (with Bia, above). Bia was visibly moved as the group offered 
heartfelt thanks to her advocacy and leadership.
“Dr. Bia changed my life,” said Marilyn E. McNee, a transplant recipient, when asked for her 
reflections. “It’s been 13 years since my transplant, and she’s always a phone call away.”
Bia, a powerful advocate for increasing the number and roles of women in medicine, was also 
instrumental in emphasizing the importance of follow-ups after surgical operations and transplants 
to patient health. She leaves behind a more integrated and patient-focused system, one in which 
discharge from a hospital is not the end of care, but rather a new beginning.
—Adrian Bonenberger
 The end  
of an era
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